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Preface 
Los hombres cultivan cinco mil rosas en un mismo jardín y no encuentran lo que 
buscan… y sin embargo, eso que buscan podrían encontrarlo en una sola rosa.1  
Sorprende esta afirmación al muchacho que por primera vez lee El Principito; ¡tal vez 
sea un recurso literario, o un producto de la imaginación que los libros de aventuras a 
veces se permiten! – esto es lo que pensaba aquel joven que en Logroño leía este libro 
con curiosidad y con inquietud por entender el mundo, y por averiguar la Verdad. En 
aquellos años de juventud, yo tampoco podía imaginarme cultivando cinco mil rosas 
para obtener una respuesta…  Sin embargo, ¡cuántas veces las he cultivado desde 
entonces!. Primero en mi “laboratorio del ático”, y también en el cuarto de baño de casa 
(gracias padres, por dejarme “investigar” y no enfadaros demasiado cuando mis 
experimentos tenían un desenlace que no os gustaba) y, más tarde, en un laboratorio de 
hospital o universidad.  
Cientos de rosas, cientos de análisis de IGF-1 y FT3. Sí, creo que en cada uno de ellos 
me hacía aquella misma pregunta y buscaba la respuesta.  
Alguien dijo – no recuerdo quién, que muchos de los grandes descubrimientos en la 
historia han surgido en el sosiego de la noche; esta persona decía que es en compañía 
de la soledad, la quietud y el silencio cuando las ideas geniales son capaces de abrirse 
camino hacia nosotros por medio de eso que algunos llaman inspiración.  Pero 
entonces, ¿qué pasa con Pierre Guillot quien, gracias a su persistencia en cultivar miles 
de Híbridos de Té en sus campos, logró crear la primera rosa de nuestra era moderna? 
Mi doctorado es parte de un camino que he recorrido desde aquellos años en los que El 
Principito me acompañara en mis libros de lectura, hasta hoy. Un camino paciente, de 
búsqueda, de esperanza, de ilusión; también, a veces, momentos de decepción, de 
desaliento.  Un camino en el que aprendes a levantarte ante cada revés, y a empezar de 
nuevo, no desde cero sino con un pasado que ya siempre te da fuerza y te acompaña. 
Un pasado lleno de agradecimiento hacia todos con los que he compartido algo en mi 
vida, especialmente mi familia, amigos y también los que no lo han sido, compañeros 
de trabajo, y ahora mi amada esposa; y gratitud hacia todos aquellos con los que me he 
cruzado en mi caminar que, aunque a veces no lo imaginen, tanto han dejado en mí.  
Y es entonces, al final de esa etapa del recorrido, cuando caminando por ese campo de 
rosas encuentras a esa que, efectivamente, es distinta a las demás. Siempre estuvo allí, y 
nunca antes la viste; nunca, hasta que pasaste junto a ella y miraste más allá.  
¿Acaso sea cierto lo que le dijo el pequeño zorro?: Lo esencial es invisible a los ojos. 
Sólo se ve con el corazón.1 
Javier José Gómez de Francisco 
 
                                                 
1
 El principito. Antoine De Saint-Exupéry 
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Resumen 
Introducción  
 No es infrecuente que en los hospitales del Reino Unido haya pacientes que 
sufran malnutrición durante su estancia y que necesiten soporte nutricional, e incluso 
nutrición parenteral (NP). En numerosas ocasiones están ingresados en unidades de 
cuidados intensivos y sus necesidades nutricionales son específicas, ya que la síntesis 
y la degradación de proteínas están incrementadas.  
 En este estudio nos hemos planteado valorar la utilidad de la insulina tipo-1 
(IGF-1) y la hormona triyodotironina libre (FT3) como marcadores bioquímicos para 
el cálculo de los requerimientos nutricionales en pacientes hospitalizados críticos que 
necesitan NP.  
 Durante el proceso de análisis de mis resultados, he observado cómo el 
número elevado, y con frecuencia inapropiado, de tests solicitados por los clínicos de 
IGF-1 y FT3 repercute negativamente en la gestión de los servicios del laboratorio. El 
número de tests bioquímicos solicitados al laboratorio de “Norfolk and Norwich 
University Hospital” aumentó el 5-10% anualmente desde 1955 hasta 2013, 
alcanzando un total de más de 15 millones de tests solamente durante el año 2014. 
Este uso inadecuado de los recursos en el contexto actual de restricción financiera en 
las economías europeas y en sus programas nacionales de salud, nos ha llevado a 
desarrollar y poner en práctica una propuesta alternativa para hacer frente a este 
problema.   
 
Métodos 
 El estudio de IGF-1 y FT3 se desarrolló en el hospital Royal Hallamshire 
(RHH). Este hospital dispone de un experimentado equipo multidisciplinar de apoyo 
nutricional encargado de atender a pacientes con NP, un tercio de los cuales están en 
la Unidad de Cuidados Intensivos (UCI). Se trató de un estudio piloto observacional 
prospectivo de 56 pacientes adultos consecutivos que iniciaron soporte con NP. Se 
midieron IGF-1, FT3 y glucosa en muestras de sangre recolectadas antes de iniciar NP 
y, posteriormente, en muestras recogidas dos veces a la semana durante dos semanas 
consecutivas. Los pacientes fueron asignados a las siguientes categorías: 
administración o no de glutamina; control de glicemia; y gravedad de la enfermedad. 
Para el análisis estadístico se utilizó un Modelo Linear Mixto del paquete estadístico 
SAS. 
 El gran incremento de tests de IGF-1 y FT3 solicitados con escasa 
justificación clínica, me llevó a desarrollar un sistema alternativo para solicitar tests 
de laboratorio. La proteína C reactiva se utilizó como modelo para estudiar el ahorro 
potencial del coste. Igualmente, se definieron y evaluaron las necesidades de los  
usuarios del laboratorio en reuniones con representantes médicos de atención primaria 
y con los grupos clínicos más relevantes de atención especializada. Se diseñaron, 
pusieron a prueba, e implementaron algoritmos para el diagnóstico bioquímico de 
numerosas enfermedades. Se implementó el proceso y un año después se diseñó y 
distribuyó una encuesta con el objetivo de recabar la opinión de estos usuarios con 
respecto a esta nueva herramienta.  
 
Resultados  
 
XIII 
 Tras el inicio de NP, las concentraciones séricas de IGF-1 y FT3 aumentaron 
linealmente entre muestras consecutivas en 15 µg/L (p<0´01) y 0.36 pmol/L 
(p<0´001) respectivamente. El nivel de glucemia y el uso de la glutamina no tuvieron 
un efecto significativo sobre estos cambios. IGF-1 fue mayor (p< 0´01) y FT3 menor 
(p<0´05) en los pacientes de UCI. Un grupo de 18 pacientes se recuperaron 
suficientemente durante el periodo de estudio como para volver a ser alimentados por 
vía oral/enteral; en éstos, el IGF-1 disminuyó significativamente al cesar la NP a pesar 
de estar ingiriendo enteralmente cantidades de nutrientes adecuadas [t (17) = 2.47, 
p<0.05]. Un subgrupo de seis pacientes desarrollaron sepsis y se observó en ellos una 
reducción de IGF-1 a pesar de recibir NP.  
 Como consecuencia del elevado, y en muchos casos innecesario, número de 
solicitudes de tests de IGF-1 and FT3 observado durante este estudio, consideré 
urgente encontrar herramientas alternativas para ayudar a investigar pacientes con 
enfermedades complejas que requieren tests bioquímicos de elevado coste o de carga 
laboral elevada.  
Igualmente sucede con la solicitud excesiva de tests de proteína C reactiva. Si 
se limitase su solicitud a un máximo de un test por cada 48 horas, esto supondría un 
ahorro de £ 19.219 (€ 23.063) por año sólo en Norfolk and Norwich University 
Hospital.  
Con este fin, se diseñaron algoritmos diagnósticos para pacientes con 
hirsutismo, disfunción eréctil, ginecomastia, galactorrea y menopausia. Estos 
algoritmos se integraron en el software del laboratorio con la colaboración de los 
servicios de informática del Departamento de Patología, y se vincularon a los 
programas informáticos utilizados para la solicitud de análisis clínicos en atención 
primaria y especializada. La encuesta a usuarios sobre la implementación de esta 
nueva herramienta destacó un entusiasta apoyo a su uso, así como al desarrollo de 
nuevos algoritmos.   
 
Conclusiones  
1. La administración de NP causó un aumento promedio de IGF-1 de 15 µg/L, y de 
FT3 de 0,36 pmol/L, indicando que las concentraciones séricas de IGF-1 y FT3 son 
marcadores sensibles que responden de manera predecible a la NP de los pacientes 
hospitalizados, tanto en UCI como en pacientes fuera de la misma.  
 
2. Sin embargo, la suspensión de la NP tiene un efecto negativo en la concentración 
de IGF-1 a pesar de la normalización de la ingesta oral/enteral. 
 
3. La aparición de sepsis durante la administración de NP provocó una caída 
significativa de los niveles plasmáticos de IFG-1. 
 
4. La cuantificación sérica de IGF-1 y FT3 pueden ser de utilidad clínica para 
optimizar el soporte nutricional de pacientes en UCI. Esto requerirá verificación con 
un estudio clínico randomizado.  
 
5. La demanda de tests bioquímicos tales como IGF-1 y FT3 se ha incrementado entre 
el 5-10% anual durante los últimos 60 años en  Norfolk and Norwich University 
Hospital. 
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6. La limitación a un máximo de un test de CPR cada 48 horas supondría un ahorro 
considerable en nuestro centro, demostrándose que la racionalización del uso de 
pruebas bioquímicas de diagnóstico tiene un impacto importante en el presupuesto de 
los servicios de patología. 
 
7. El uso de algoritmos de diagnóstico tiene una excelente aceptación entre los 
profesionales de la salud. Los clínicos perciben a esta herramienta como un 
instrumento muy útil para optimizar el número de pruebas analíticas tanto para el 
diagnóstico como para el seguimiento de pacientes; para reducir el número de citas 
innecesarias y evitables; para incrementar la calidad de la atención a los pacientes, así 
como para disminuir el coste cada vez mayor de las investigaciones bioquímicas. 
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Summary 
Rationale:  
 Short term starvation is a frequent occurrence in UK hospitals. Such patients 
are frequently in intensive care units (ICU) and may require nutritional support, which 
may need to be administered as parenteral nutrition. However, the nutritional needs of 
patients on ICU differ from other groups of patients as synthesis and also degradation 
of proteins are increased.  
 We thought it would be valuable to investigate if IGF-1 and FT3 would be 
suitable biochemical markers that could be used in the optimization of provision of 
Total Parenteral Nutrition (TPN) in hospitalised patients. To this aim we have 
investigated their possible variation in relation to the administration of TPN.  
 During the analytical phase of this study, I have observed the elevated – and 
frequently inappropriate,  number of IGF-1 and FT3 requests for the diagnosis and 
management of patients. The workload at Norfolk and Norwich University Hospitals 
has increased at an annual rate between 5-10% every year since 1955, with more than 
15 million biochemistry analyses expected only in this Trust during 2014. The 
inappropriate use of laboratory services is of particular relevance in the current 
European context of financial strain of the national health systems. As a result, I have 
proposed, developed and put in practice a strategy to address this problem.  
 
Materials and methods:  
 The Royal Hallamshire Hospital (RHH) has a well established Nutrition 
Support Team (NST) responsible for looking after patients on TPN, one third of 
whom are based on ICU. Fifty six correlative adult patients starting TPN were 
recruited. The study was designed as a prospective observational pilot research. Blood 
specimens were collected before starting TPN and twice weekly thereafter. Serum 
IGF-1, FT3 and glucose were measured. Patients were categorised on the basis of the 
use of glutamine or not, glycaemic control and severity of illness. A Mixed Linear 
Model was used for the statistical analysis.  
 The exponential increase of IGF-1 and FT3 test requests, in many cases not 
clinically justified, prompted me to develop new approaches to cover the needs that 
traditional requesting of tests is causing in the new emergent automated laboratories. 
To this aim, CRP was used as a model to evaluate the potential cost savings. The 
requirements of users of laboratory services were discussed at meetings organised 
with primary care representatives and the most relevant secondary care users. 
Laboratory diagnostic algorithms were produced, tested and implemented. 
Information circulars were produced and distributed, as well as a survey to evaluate 
the effect of its implementation on users.  
 
Results:  
 Initiation of TPN was followed by a linear increase of IGF-1 by 15 µg/L 
(p<0.01) and of FT3 by 0.36 pmol-L (p<0.001) between consecutive samples. Poor 
glycaemic control and use of glutamine had no significant effect on these changes. 
Patients on ICU had higher IGF-1 and FT3 (p<0.01 and p<0.05 respectively). Patients 
who reverted to oral/enteral feed had a marked reduction of IGF-1 after 
discontinuation of TPN despite meeting nutrition requirements [t (17) = 2.47, p<0.05]. 
 
XVII 
In the subgroup of six patients who developed sepsis whist on TPN, a reduction of 
IGF-1 but not FT3 was observed.  
 Based on the observed elevated number of requests, and unnecessary in many 
cases, of IGF-1 and FT3 during my studies, it was urgent to look for diagnostic tools 
to assist with the investigation of patients with complex diseases that required manual 
or very costly laboratory tests.  
Similarly, restriction of CRP requests to a maximum of one every 48 hours 
would imply annual savings of £ 19.219 (€ 23.063) only at Norfolk and Norwich 
University Hospital.  
With this aim, algorithms for patients with hirsutism, erectile dysfunction, 
gynaecomastia, menopause and galactorrhoea were produced, integrated in the 
laboratory software, and linked to the computer programs used for requesting 
investigations in primary and secondary care. The results of the evaluation survey 
about this new diagnostic tool highlighted the usefulness and strong support for 
further development.  
 
Conclusions:  
1. The administration of PN resulted in a mean increase between samples of 15 µg/L 
for IGF-1, and of 0.36 pmol/L for FT3, indicating that serum concentration of IGF-1 
and FT3 are sensitive markers that respond predictably to the initiation of PN in both 
ICU and non-ICU hospital wards, 
2. However, discontinuation of PN has a negative effect on IGF-1 concentration 
despite a normalized enteral intake.  
3. New onset of sepsis caused a significant fall of IFG-1 while on PN.   
4. Measurements of IGF-1 and FT3 may be useful in the optimization of nutrition 
support in the Intensive Care Unit.  To verify this, a randomised double blind trial is 
needed. 
5. There has been a systematic and persistent increase of 5-10 % during the last 60 
years in demands of biochemistry tests such as IGF-1and FT3 in Norfolk and 
Norwich University Hospital.  
6. Limiting the maximum number of CRP tests to one per 48 hours makes important 
savings at Norfolk and Norwich Hospital, showing that the rationalization of 
biochemistry tests requesting has a marked impact in the budget of pathology 
services. 
7. The use of diagnostic algorithms in medical care has excellent acceptance among 
healthcare professionals. Primary care physicians perceive this tool as an instrument 
to reduce the number of blood tests, reducing the number of unnecessary and 
preventable patients‟ appointments, improving the quality of care of patients and the 
overall patients‟ healthcare experience, and minimising the escalating cost of 
biochemical investigations. 
 
 
I confirm that this dissertation is my own work. 
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1. Introduction  
1.1 Historical perspective of parenteral nutrition 
The origins of TPN date back 350 years.  There are early anecdotal studies, such as 
that of Sir Christopher Wren on intra-venous infusions of wine, ale and opiates in a 
dog in 1665; or the successful water and salts infusions into cholera patients by the 
Scottish physician Latta in 1831.  
Practical clinical use of PN, however, did not materialize until the 1960s, based on 
research developed since the 1930s by authors such as the Nobel price Whipple and 
associates with their studies on protein requirements (Holman RL, Mahoney EB et al. 
1934; Whipple GH and Madden SC 1944); or Robert Elman, who published the first 
successful study evaluating the intra-venous infusion of amino acids in the form of a 
fibrinogen hydrolysate in man (Elman R 1937; Elman R and Weiner DO 1939).  It 
was not until 1944 that the first hydrolysate was marketed (Wretlind KAJ 1947), and 
in 1961 the first non-toxic lipid emulsion was developed (Schuberth O and Wretlind 
A 1961).  The first crystalline L-amino acid solution was introduced in 1964 by Bansi 
in Germany.  
In the UK, about 5% of the population are estimated to be malnourished (Gregory J 
1990). Undernutrition was already documented in UK hospitals in 1974 (Bistrian, 
Blackburn et al. 1974; Hill, Blackett et al. 1977). More recently, the British 
Association of Parenteral and Enteral Nutrition (BAPEN NSW) reported a 27% risk 
of malnutrition in hospitalized patients under 30 years of age, and a 34% risk for those 
over 80 years of age (BAPEN NSW 2007). In Spain, 20% of patients are at risk or 
with moderate malnutrition at the time of hospital admission, and 18.2% are classified 
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as severe (Cereceda Fernandez, Antolin Juarez et al. 2003). This evidence confirms 
that malnutrition is still a common and frequently unrecognised occurrence.   
Poor nourishment contributes to delayed wound healing, impaired immunity, reduced 
stamina, muscular weakness and functional disability, reduced cardiac and respiratory 
capacity and reduced body protein reserve (Hoffer LJ 1999).  It has been linked to a 
higher incidence of post-operative complications and longer recovery time, which 
increases patients‟ morbidity and mortality (McWhirter and Pennington 1994; Potter, 
Langhorne et al. 1998). 
1.2 Estimation of nutritional requirements 
In an attempt to calculate nutritional requirements, numerous researchers and 
specialists in nutrition have suggested formulas based on basal metabolism, metabolic 
response to food, physical activity, or physiological context.  However, the 
formulation of equations for hospitalised patients is complex as both anabolism and 
catabolism are increased after pathological factors such as trauma or major surgery 
(Arnold, Campbell et al. 1993).   
The League of Nations proposed the first internationally recognised recommendation 
of macronutrients requirements in 1936.  And, after the Second World War, the risk 
of energy and protein deficiency in the diet of developing country populations was 
considered to be high for the first time.  In 1950, the F.A.O. organised an Expert 
Consultation and made recommendations for population groups with defined patterns 
of physical activity (men, women and children) but not for 
individuals(FAO/WHO/UNU 2004).  Further recommendations were published in 
1957, 1973 and 1985.  The data obtained in the latter report was followed by an in-
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depth statistical analysis by Schofield and colleagues which lead to the publication of 
a series of predictive equations (Schofield 1985 ).  Other authors have developed 
formulas for specific groups of patients supported by newly developed techniques 
such as Doubly-Labelled Water (DLW) (Ireton-Jones CS, Turner WW et al. 1992).   
1.2.1 Limitations of formulas for the calculation of requirements in hospitalised 
patients 
The proposed equations have been criticized because they may under or over-estimate 
needs in comparison to the measured energy expenditure. This may be of particular 
relevance in critically ill patients in whom the apparent severity of the illness may 
induce to overestimate the applied correction stress factor (Cortes and Nelson 1989).  
The Schofield equation is more commonly used in parts of Europe, while Harris-
Benedict Equation (HBE) has traditionally been used in the United States – now 
partly replaced by the 2005 US Guideline which was based on the 2002 report of the 
Institute of Medicine (Trumbo, Schlicker et al. 2002), but also in some European 
countries.  
The Schofield equation was developed in 1985. The original study included 7173 
healthy individuals and was overrepresented with military Italians adults 
(approximately 2200 of the total). The age of the population pool was skewed towards 
the young, with only 88 people over the age of 60. Schofield equations do not include 
height as a variable (Reeves and Capra 2003).  
The Harris-Benedict formula was developed with data from 1919. The participants 
(136 males and 103 females) were healthy, with height and BMI in line to population 
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living more than 100 years ago – BMI 21.4 ± 2.8 and 21.5 ± 4.1 for males and 
females respectively (Harris and Benedict 1918). Obese and malnourished patients 
were therefore underrepresented. 
Studies comparing the measured BMR of healthy Western mixed lean and obese 
populations with that calculated with the HBE have concluded that the requirements 
are overestimated with this equation (Owen, Kavle et al. 1986; Owen, Holup et al. 
1987; Mifflin, St Jeor et al. 1990).  
Patients who are malnourished have increased Basal Metabolic Rate (Donahoe, 
Rogers et al. 1989). The HBE can predictably calculate the BMR of normally 
nourished patients with similar physical characteristics to those included in the 
original study, but it is unreliable in those malnourished (Roza and Shizgal 1984).  
In obese women (mean BMI 38.9 ± 7.4) only 59% of patients had a measured BMR 
within 10% of the predicted value (Foster, Wadden et al. 1988). Other authors argue 
that HBE may be still applicable in moderate obesity (Frankenfield, Muth et al. 1998).  
Therefore, the validity and applicability of Schofield formula and HBE to the Western 
populations has to be determined.  
As reported by Reeves, more recently published formulas have shown to have poor 
predictive value, are based on individuals that are not representative of the general 
population, and have large standard errors for the estimate (Reeves and Capra 2003). 
Some formulas have been developed for specific diseases or injuries as burns or for 
patients in CCU (Allard, Pichard et al. 1990; Swinamer, Grace et al. 1990). However, 
factors such as the diversity of concomitant diseases that might affect these patients, 
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or the severity of the diseases, make the standardization of these calculations 
complex.  
In a study of 37 acutely ill children who had been mechanically ventilated for more 
than 24 hours, gross overestimation of daily allowances and energy expenditure was 
described if the recommended formulas were used, including Schofield and HBE 
(Briassoulis, Venkataraman et al. 2000).  
Further to the above and more importantly, in acutely ill and post-surgical patients, 
improved metabolic and clinical outcome has been reported if calories are provided at 
below the calculated requirements (Patino, de Pimiento et al. 1999; Jiang, Sun et al. 
2011). These findings suggest that the optimal metabolic response of acutely ill 
patients depends on the adequate provision of energy, and these nutrition 
requirements are not only based on the standard parameters used in healthy 
individuals (height, BMI, or even nutritional state) but also on factors dependant on 
the intrinsic metabolic adaptive response triggered by the critical illness.  
Generic formulas may therefore not be applicable in hospitalised patients. 
In this context, provision of appropriate parenteral nutrition support continues to be a 
challenge in acutely ill patients. 
1.3 Nutrition supplementation in hospitalised patients  
Numerous studies have proved the benefit of early nutrition in patients who are 
hospitalised. The immunologic function is enhanced as shown by the increased CD4 
cells and CD4-CD8 ratios in patients with severe head injury (Sacks, Brown et al. 
1995); also biochemical parameters, which include albumin and haemoglobin, show 
statistically significant improvement (p<0.05) in the first week of treatment (Zhang, 
 
8 
Dong et al. 2004). From the clinical perspective, the Veteran‟s Affairs Cooperative 
Study randomised a group of 395 patients who required major surgery to either pre 
plus post-surgical PN or to no perioperative PN. In this study, patients who were 
categorised as severely malnourished had significantly less incidence of healing 
complications, and had no increase in infectious complications (5% versus 43%; p = 
0.03). These results did not mirror the findings in the group of patient who were 
borderline or mildly malnourished (The-Veterans-Affairs-Total-Parenteral-Nutrition-
Cooperative-Study-Group 1991). Similar findings have been described after severe 
abdominal trauma (Moore and Jones 1986).  
Kondrup et al analysed a series of 128 randomised clinical trials and classified the 
patients according to nutritional status and severity of disease in absent, mild, 
moderate or severe undernutrition. He described that among the 75 studies of patients 
classified as nutritionally at-risk, 43 showed a positive effect of nutritional support on 
outcome. However, of 53 studies which included a high percentage of patients 
considered not to be at nutritional risk, only 14 showed any positive effect 
(P=0.0006). This corresponded to a likelihood ratio (true positive/false positive) of 
1.7 (95% CI: 2.3-1.2). The likelihood ratio of the 71 studies of parenteral nutrition 
was 1.4 (1.9-1.0), and that for 56 studies of enteral or oral nutrition was 2.9 (5.9-1.4). 
The analysis of this group of controlled trials concluded that patients more 
malnourished or at more risk of malnutrition were more likely to benefit of nutritional 
intervention (Kondrup, Rasmussen et al. 2003).   
The benefits of nutrition intervention have also been observed in infants. Days 
required of parenteral nutrition, time to reach full enteral feeding, days on mechanical 
ventilation, length of aminophylline use, and time required to regain birth weight were 
improved if early nutrition was provided in comparison to babies who received 
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supplementation more than 48 hours after birth (Ho, Yen et al. 2003); Donovan et al 
described a rapid and improved weight gain after early initiation of nutrition support 
in extremely low-birth-weight infants, which enhanced earlier achievement of full 
enteral feeding (Donovan, Puppala et al. 2006); a retrospective comparison before and 
after the implementation of a protocol of early feeding for patients in the Paediatric 
Intensive Care Unit showed a reduction from 57.8 hours and a median of 32 hours to 
18.5 hours and a median of 14 hours (p < .0001). A reduction in the percentage of 
patients vomiting (from 20% to 11%) and constipation (from 51% to 33%) was also 
noted (Petrillo-Albarano, Pettignano et al. 2006). 
The effects of nutritional supplementation in hospitalised patients have also been e 
valuated after discharge. In a study with 101 malnourished patients, Beattie again 
described significantly more morbidity, worse quality of life and, very importantly, a 
declined nutritional status for two months after discharge, in those patients who did 
not receive nutritional supplementation in comparison with those who did (1.5 kcal/ml 
and 0.06 g/ml of protein) (Beattie, Prach et al. 2000).  
The consistency of these findings in the literature has been reflected in national and 
international guidelines, such as the European Society for Clinical Nutrition and 
Metabolism (Singer, Berger et al. 2009), and the American Society for Parenteral and 
Enteral Nutrition (McClave, Martindale et al. 2009), the National Institute for Health 
and Clinical Excellence of the United Kingdom (National Collaborating Centre for 
Acute Care 2006), and the consensus of the Sociedad Española de Medicina 
Intensiva, Cuidados Críticos y Unidades Coronarias and the Sociedad Española de 
Nutrición Parenteral y Enteral (SEMICYUC-SENPE) (Mesejo, Vaquerizo Alonso et 
al. 2011).  
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1.4 Parenteral versus enteral nutrition 
The literature supports the benefits of EN versus PN in trauma, surgical and severely 
ill non-surgical patients. Moore et all, in 1989, described lower septic morbidity (3% 
versus 20%) and better restoration of the traditional nutritional markers albumin, 
transferring and retinol-binding protein if enteral versus parenteral nutrition was 
provided to patients with abdominal trauma (Moore, Moore et al. 1989). Other 
authors have reported similar findings in trauma patients (Kudsk, Croce et al. 1992), 
in medical patients with acute pancreatitis (Petrov, Kukosh et al. 2006), or patients on 
CCU (Demeyer, Bataillie et al. 1994). Improved intestinal barrier function has also 
been associated with enteral feeding (Xu, Huang et al. 2011), as well as bacterial 
translocation from the gut is promoted with PN (Alverdy, Aoys et al. 1988). Yang et 
al demonstrated significant changes in the mucosal lymphoid population with TPN, 
leading to a rise in interferon gamma, a decline in interleukin-10 expression – both of 
which contribute to the loss of enteral barrier function, and a decline in the expression 
of tight junction and adherens junction proteins (Yang, Feng et al. 2009).  
A comparison of randomised controlled trials by Gramlich found that enteral 
nutrition, as opposed to parenteral nutrition, had resulted in an important decrease in 
the incidence of infectious complications in the critically ill, and also in significant 
cost savings. This review included patients with head trauma and injuries, abdominal 
trauma, sepsis, cardiac bypass, and severe acute pancreatitis, and concluded that 
enteral nutrition should be the first choice for nutritional support in the critically ill 
(Gramlich, Kichian et al. 2004).  
The preference of the enteral route was confirmed in another systematic review with 
critically ill and perioperative patients, even though this study reported an increased 
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favour for combined enteral-parenteral therapy in cases with sustained hypocaloric 
enteral nutrition (de Aguilar-Nascimento and Kudsk 2008).  
More recently, in the meta-analysis performed by Li et al, lower mortality, fewer 
infectious complications, decreased organ failure and surgical intervention rate were 
associated to total enteral nutrition in comparison to TPN support (Yi, Ge et al. 2012).  
However, there is a very important subset of patients in whom the enteral route is not 
a valid option and, although invasive, PN is the only mean to provide nutrition. As 
described in the National UK Guidelines, this group includes patients with inadequate 
or unsafe oral/enteral intake or with a non-functional inaccessible or with perforated 
gastrointestinal tract (National Collaborating Centre for Acute Care 2006). Parenteral 
nutrition is a valid, necessary and, sometimes, life-saving alternative in these 
situations.   
Patients with sustained hypocaloric enteral nutrition form a third therapeutic group.  
In these patients, combined enteral-parenteral may also be beneficial as prolonged 
hypocaloric nutrition should be avoided. However, as highlighted by De-Aguilar, the 
precise caloric target remains controversial (de Aguilar-Nascimento and Kudsk 2008).  
1.5 Indications of parenteral nutrition 
In our study we were guided by NICE recommendations (National Collaborating 
Centre for Acute Care 2006) who classify patients in two categories: malnourished 
and those at risk of malnutrition. However, other guidelines take a more specific 
approach. The European Society for Parenteral and Enteral Nutrition (ESPEN) makes 
recommendations for specific groups of patients (intensive care, gastroenterology, 
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renal failure, pancreatic disease, surgery, hepatology, non-surgical oncology, home 
PN, cardiology and pneumology, geriatrics) (Anker, Laviano et al. 2009; Bozzetti, 
Arends et al. 2009; Braga, Ljungqvist et al. 2009; Cano, Aparicio et al. 2009; 
Gianotti, Meier et al. 2009; Plauth, Cabre et al. 2009; Singer, Berger et al. 2009; 
Sobotka, Schneider et al. 2009; Staun, Pironi et al. 2009; Van-Gossum, Cabre et al. 
2009).  
This initiative has been followed by the Metabolism and Nutrition Working Group 
(GTMyN) of the Spanish Society of Intensive Care Medicine and Coronary Units 
(SEMICYUC) with recommendations for the different populations of critically-ill 
patients, as well as recommendations for complementary PN (defined as the 
administration of PN supplemental to EN when the calculated nutritional 
requirements of the patient are not met with enteral intake only). In the Spanish 
guidelines, complementary PN should be started when 60% of nutritional 
requirements are not met at the fourth day of admission, or for at least 2 consecutive 
days during the hospital stay (Mesejo, Vaquerizo Alonso et al. 2011). 
The review of Heighes et al included five systematic reviews with a total of 30 
clinical trials. These studies focused on acutely hospitalised patients, critical illness, 
burns, elective intestinal surgery and pancreatitis. It was found that, even though there 
was variability in the evidence regarding the benefits of early EN, the mortality 
significantly reduced in elective intestinal surgery patients (RR = 0.41, 95% 
confidence interval 0.18 to 0.93, p = 0.03) as well as the infectious complications in 
acutely ill hospitalised patients (relative risk 0.45, 95% confidence interval 0.3 to 
0.66, p = 0.00006) (Heighes, Doig et al. 2010). In another review of three randomised 
controlled trials with 126 participants, the provision of early EN was associated with a 
significant reduction in mortality (OR = 0.20, 95% confidence interval 0.04-0.91). 
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However, this conclusion was taken with caution as the trial size was small, and the 
overall quality of the studies were considered low (Doig, Heighes et al. 2011).  
In view of these results, it has been suggested that the benefits of early administration 
of PN might outweigh the detrimental effects of a late initiation of EN in those cases 
where the utilization of the enteral route is delayed and the achievement of the 
nutritional objectives affected. However, the inflexion point where the benefits of 
early PN outweigh its potential risks is still unclear. The controversy about the timing 
of introduction of PN has been approached differently by different countries. For 
example, ESPEN recommends commencing PN after two days if patients are below 
the EN target. In contrast, the American Society for Parenteral and Enteral Nutrition 
(ASPEN) recommends waiting until day eight (Heyland, Dhaliwal et al. 2003; 
Martindale, McClave et al. 2009).  
1.6 Routes of access 
PN feeds have elevated osmolarity and should be delivered into a vein with high 
blood flow, usually in the superior vena cava at the entrance of the right atrium. 
However, the route of this central access varies depending on local expertise and 
practises, and the duration of the PN. The options include:  
 Peripherally inserted central catheter (PICC): generally used if PN is required 
for a prolonged period of time. However, the use of this device is also 
becoming more frequent in short-term PN due to its reduced incidence of 
severe complications such as traumatic pneumothorax or uncontrollable bleed. 
Insertion of a PICC is an aseptic technique, but does not generally require the 
skills of a surgeon of physician.   
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 Central venous lines: limited in duration due to frequent infection. The 
commonest access is subclavian or internal yugular.  
 Tunnelled lines: aims to reduce the incidence of systemic infection caused by 
central lines by creating a „tunnel‟ or subcutaneous track. It requires sedation 
or general anaesthetic, and allows long-term PN.  
1.7 Complications of parenteral nutrition 
Premature gastric feed in a context of enteral intolerance can lead to serious 
consequences. Parenteral nutrition may be appropriate in these situations.  
Even though PN is generally regarded as a safe clinical intervention, multiple possible 
complications have been described. For ease of description, these have been grouped 
in the following categories: 
1.7.1 Technical complications associated to the vascular access 
Phlebitis and damage of the vein are not uncommon. They may be caused by direct 
thrombogenic effect of the line or by the elevated osmolality of the PN mixture. The 
elevated osmolality of the PN requires administration into a high blood flow vein, 
usually the vena cava at its entrance to the right atrium. Comparative studies with 
other central lines suggest that PICC access does not result in an increased rate of 
sepsis or thrombosis, but have an increase incidence of local complications such as 
phlebitis, leaking catheter or rupture of the line (Duerksen, Papineau et al. 1999).  
Cardiac perforation caused by the advancement of the tip of the central catheter due to 
the arm movements has been described (Jaurrieta-Mas, Rafecas et al. 1982; Krog, 
Berggren et al. 1982).   
 
15 
Air embolism is infrequent but potentially fatal. The greatest risk of this complication 
occurs during the insertion of the catheter and during the manipulation of the 
connection between the catheter and the administration set. This risk can be 
minimized by assuring a positive venous pressure with the patient in supine or 
Trendelenburg‟s position whenever there may be risk of air entering into the infusion 
system.  
1.7.2 Mechanical complications 
Misplacement of the catheter may happen. This could be intra or extra vascular. The 
commonest intra vascular malposition is the homolateral internal jugular. Extra 
vascular malpositions may lead to hydrothorax, hemothorax or cardiac tamponade, 
depending if the pleura (without or with arterial affectation) or the heart cavity (right 
atrium most probably) are affected.  Correct position of the patient is an essential 
factor to maximize the chances of success (Boyd, Saxe et al. 1996).  
Other less frequent mechanical complications include accidental withdrawal, rupture, 
arterial puncture, pneumothorax and mediastinal haematoma (King 1971; Mansfield, 
Hohn et al. 1994; Vidal, Muller et al. 2008).  
1.7.3 Metabolic complications  
These are associated with the excess or defect of nutrients. Hypophosphataemia and 
hypokalaemia as a consequence of refeeding syndrome are not uncommon. Other 
blood dyscrasias include abnormal concentrations of sodium, glucose, triglycerides, 
water balance, liver function tests, vitamins and trace elements, essential fatty acids 
etc.  
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1.7.4 Hepato-biliary complications 
Steatosis is the commonest histological finding in adult patients. This can be 
prevented by the concomitant consumption of nutrients via the enteral route (Angelico 
and Della Guardia 2000). The combination of gamma-glutamyl transpeptidase and 
alkaline phosphatase is the most cost effective way of detecting PN associated 
cholestasis (Nanji and Anderson 1985).  
Hepato-biliary complications may also present with intrahepatic cholestasis, 
steatohepatitis, and fibrosis including cirrhosis (Bowyer, Fleming et al. 1985).  
Extra-hepatic complications such as gallbladder distension, cholelithiasis and 
gallstones may happen.  Messing et al reported biliary sludge in 6% of patients after 
three weeks of commencing PN, which increased to 50% within four to six weeks, 
and affected the totality of patients in the study after 6 weeks of PN usage (Messing, 
Bories et al. 1983).  
1.7.5 Catheter-related infections 
This is one of the commonest complications of CVC‟s and is potentially fatal. Various 
factors have been identified to increase the risk of sepsis. These include congestive 
heart failure, intra-abdominal perforation, Clostridium difficile infection, recent 
chemotherapy, presence of tracheostomy, and characteristics of the catheter 
(Pongruangporn, Ajenjo et al. 2013). 
PICC lines have a reported lower risk of infection than other standard CVCs (Gunst, 
Matsushima et al. 2011).  
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1.8 IGF-1 
Growth hormone-dependent growth factors (IGF-1 and IGF-2) are polypeptide 
hormones with four domains designated A, B, C, and D.  The A and B domains are 
homologous with the A and B chains of insulin.  Insulin-like growth factors were 
termed sulphation factors or somatomedins in the past, but the name was later 
modified to insulin-like growth factors because of this structural homology to insulin 
– it has been found that the insulin/IGF-1 pathway drives an evolutionary conserved 
mechanism that regulates lifespan and longevity (Bonafe, Barbieri et al. 2003).  
From a nutritional perspective, a multi-centre cross-sectional analysis of 1142 men 
and 3589 women identified a positive relationship between BMI and IGF-1 (Crowe, 
Key et al. 2011).  
In a study with six patients, Clemmons et al. found that IGF-1 had more prompt and 
marked increase response to nutrition than prealbumin, transferrin or retino-transfer 
protein (Clemmons, Underwood et al. 1985).  
During fasting there is a decline in binding of GH to its hepatic receptor which 
decreases the transcription of GH receptor mRNA (Bornfeldt, Arnqvist et al. 1989; 
Straus and Takemoto 1990).  The consequence of these changes is a reduction of 
hepatic IGF-1 synthesis.  Conversely, an increase in circulating IGF-1 follows 
refeeding (Ketelslegers, Maiter et al. 1995).  
IGF-1 is secreted as it is produced – there are no organs in which it concentrates and, 
therefore, synthesis is closely linked to circulating blood concentration, though it 
circulates complexed to binding proteins (IGFBPs) in blood. It acts via its cognate 
receptor and is a potent natural activator of MAP kinase, PI 3-kinase, c-AMP/protein 
kinase A, and protein kinase B signalling pathways (Alessi, Andjelkovic et al. 1996; 
 
18 
Makarevich, Sirotkin et al. 2000).  This receptor has approximately 70% homology 
with the insulin receptor (Ullrich, Gray et al. 1986). 
While IGF-2 is thought to have a primary role in foetal development (Roberts, Owens 
et al. 2008) whist IGF-1 is required for achieving maximal growth in adults.  Specific 
functions of IGF-1 have been described in growth, proliferation and differentiation of 
cells (Baserga, Sell et al. 1994; Engert, Berglund et al. 1996; Sasaoka, Ishiki et al. 
1996). IGF-1 inhibits lipolysis, increases glucose oxidation in adipose tissues, and 
stimulates glucose and aminoacids transport into cells (Yorekl, Dunlap et al. 1987; 
Fang, Mao et al. 2006). IGF-1 also stimulates intestinal mucosal growth (Young, 
Taranto et al. 1990; Lemmey, Martin et al. 1991). In human volunteers, 
administration of intravenous IGF-1 directly increases protein synthesis in skeletal 
muscle – provided that aminoacids supply is adequate (Fryburg 1994; Russell-Jones, 
Umpleby et al. 1994).   
More recently, this role of IGF-1 in nutrition has been reinforced with observations as 
those by Elnenaei, who has described IGF-1 as a sensitive and specific marker for 
predicting refeeding (defined in his article as 30 % decrease in phosphate 
concentration within 12-36 hours after starting PN). Moreover, this group has 
included IGF-1 in the calculation of the 'Refeeding index', defined as leptin x IGF1 
divided by 2800 to produce a ratio of 1.0 in patients who are well nourished, 
producing a sensitivity of 78 %; 95 % CI 40, 97 %) and specificity (78 %; 95 % CI 
40, 97 %) with a likelihood ratio of 3.4, at a cut-off value of 0.19 for predicting 
refeeding syndrome (Elnenaei, Alaghband-Zadeh et al. 2011). This same author has 
also described that concentration of IGF-1 pre-PN is a predictor of mortality.  
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1.8.1 Evidence of inflammatory factors affecting IGF-1 
Inflammation and IGF-1 has been associated by numerous authors. For example, in 
macrophages, IGFs promote the release of proinflammatory cytokines  (Bayes-Genis, 
Conover et al. 2000). At the same time, hypermetabolic sepsis and critical illness has 
been described to reduce plasma IGF-1 and IGFBP-3 concentrations (Ross, Miell et 
al. 1991; Wojnar, Fan et al. 1995; Cotterill, Mendel et al. 1996).  Similarly, as 
reported by Sukhanov, an increase in circulating IGF-1 reduces vascular 
inflammatory response in mice (Sukhanov, Higashi et al. 2007).  
Tumour Necrosis Factor (TNF) is a cytotoxin secreted during sepsis and trauma 
(Chen, McKinnon et al. 1985; Gurram, Chirmule et al. 1994; Ferguson, Taheri et al. 
1997).  TNF has been shown to suppress the tyrosine kinase Janus Kinase/Signal 
Transducer and Activator of
 
Transcription (JAK/STAT) pathway by inhibiting the 
interaction
 
of the GH receptor with JAKs as well as JAK tyrosine kinase
 
activity 
(Endo, Masuhara et al. 1997; Naka, Narazaki et al. 1997).  This leads to a decrease of 
IGF-1 mRNA and, ultimately, to a reduction in IGF-1 synthesis in liver and muscle 
(Johnson, O'Leary et al. 2001).  
Other inflammatory mediators – endotoxins, interleukin-1[beta] and interleukin-6, and 
glucocorticoids – have also been reported to cause similar effect in the JAK/STAT 
pathway (Fan, Molina et al. 1994; Fan, Li et al. 1995; Lang, Fan et al. 1996; Takeda, 
Kurachi et al. 1998).  
More recently, Farquharson describes how pro-inflammatory cytokines alter both 
GH/IGF-1 signalling and cellular function (Farquharson and Ahmed 2013).  
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1.8.2 Evidence of insulin resistance causing low IGF-1 
IGF-1 is reduced in insulin-resistant states with or without diabetes mellitus (DM) 
(Sesti, Sciacqua et al. 2005).   
Initial studies in children with new-onset of diabetes (DM) type 1 suggested that 
insulinopenia was largely responsible for the IGF-1 reduction (Bereket A 1995; 
Thorell, Nygren et al. 1999).  However, IGF-1 is also reduced in individuals with 
uncontrolled DM (Bereket A 1995), in metabolic syndrome and in insulin-resistant 
states with or without DM (Sesti, Sciacqua et al. 2005).  Therefore, it has been 
suggested that the insulin resistance state itself is the causative factor of IGF-1 
reduction.   
This hypothesis has been confirmed by studies which show that IGF-1 enhances 
insulin sensitivity, reduces insulin requirements, and
 
improves glycaemic control in 
subjects with DM type 2 and syndromes with insulin resistance (Morrow, O'Brien et 
al. 1994; Clemmons, Moses et al. 2000; Clemmons, Moses et al. 2005).  
1.8.3 Correlation between protein/aminoacids intake and serum IGF-1 
IGF-1 declines after protein or calorie restriction (Smith, Underwood et al. 1995), and 
both protein and energy are needed to restore circulating IGF-1 concentrations after 
fasting (Isley, Underwood et al. 1983).  This has recently been confirmed by Henning 
who, in a double blind placebo controlled trial of 27 subjects, described a decrease of 
7% during calorie restriction (Henning, Scofield et al. 2013).  
Donahue and Phillips, however, suggested that proteins have more predominant role 
than total energy in IGF-1 regulation.  They compared a group of protein 
malnourished patients with another group of malnourished patients due to energy 
restriction, and found that changes in IGF-1
 
were positively correlated with nitrogen 
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balance (r = 0.45, p less than 0.005) (Donahue and Phillips 1989).  Also Underwood 
found a highly positive correlation (r = 0.9) between change in IGF-1 and change in 
nitrogen balance during fasting and refeeding (Underwood 1999), suggesting that 
variations in serum IGF-1 reflects variations in protein metabolism. This appears to be 
explained by both changes in the production rate of IGF-1 and its clearance (Thissen, 
Davenport et al. 1992).  Thissen observed that serum clearance of IGF-1 was 
increased by 58% in protein restricted rats (Thissen, Davenport et al. 1992).  
Similarly, Ketelslegers et al observed that protein malnutrition enhanced IGF-1 serum 
clearance and down-regulated IGFBPs (Ketelslegers, Maiter et al. 1996; Takenaka, 
Mori et al. 1996). 
Despite the inverse relationship between inflammation and IGF-1, this correlation 
between protein intake and IGF-1 has been reported to be preserved during the acute 
phase response when CRP is in the range from 40 to 248 mg/L (Burgess 1992). 
1.9 Free T3 
Approximately 20% of T3 is produced in the follicular cells of the thyroid gland by 
coupling diiodotyrosine with monoiodotyrosine (Pilo, Iervasi et al. 1990).  T4 is also 
secreted in the follicular cells, and in greater quantity than T3, but T3 is several times 
more potent.  Both are lipid soluble and easily diffuse through the plasma membrane.  
Once in the intracellular space, T4 can be converted to T3 by removal of an iodine 
atom (Pisarev 1985), contributing the remaining 80% of circulating T3.  
T3 circulates in plasma bound to carrier proteins which conforms a reversible binding 
equilibrium.  The proteins that carry 95% of the hormone are thyroxine-binding 
globulin (TBG), transthyretin (or pre-albumin), and albumin.  A minor proportion is 
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bound to lipoproteins.  Only 0.3% of T3 remains unbound, but it is this free fraction 
that is metabolically active at tissue level (Burtis CA 2005).  
Thyroid hormones are regulators of the metabolism of various tissues, but most 
thyroid actions are mediated
 
by T3.  They play a significant metabolic role influencing 
cell respiration, free radical production,
 
and energy homeostasis (Braverman LE 
2004).  
Thyroid hormones enhance the effect of insulin on glycogen synthesis, increase the 
utilization of glucose by myocytes and adipocytes, and potentiate the rate of intestinal 
absorption of glucose and galactose (Van den Berghe 1999). 
1.9.1 Evidence of correlation between diet and FT3 
Thyroid hormones enhance the effect of insulin on glycogen synthesis, the utilization 
of glucose by myocytes and adipocytes, and potentiate the rate of intestinal absorption 
of glucose and galactose (Van den Berghe 1999). 
Data from studies conducted in rodents have shown that calorie restriction decreases 
serum T3 concentrations, whereas serum
 
T4 and TSH usually remain unchanged 
(Herlihy, Stacy et al. 1990; Maglich, Watson et al. 2004).  Similarly, another study in 
rodents and monkeys with long term calorie restriction but adequate intake of proteins 
and micronutrients evidenced decreased FT3, whereas FT4 or TSH remained 
unchanged (Herlihy, Stacy et al. 1990; Maglich, Watson et al. 2004).  This same 
effect has been observed in humans who underwent a calorie deprivation diet with 
protein supplementation (Kaptein, Fisler et al. 1985; Fontana, Klein et al. 2006).  In 
this same study, it was suggested that changes in thyroid hormones might facilitate 
conservation of visceral protein and reduce muscle protein turnover.  Further along 
this line, in a study with eight groups of obese patients, Pasquali et al have observed 
 
23 
that T3 was only affected by calorie restriction when the intake of carbohydrates was 
less than 120 g/day, independently of the total calorie intake (Pasquali R 1982).  
Similar findings have been
 
reported in a study of eight non-obese individuals who 
voluntarily followed a calorie-restriction diet for 2 years (Walford, Mock et al. 2002).  
Fernández-Reyes described that serum FT3 – but not FT4 or TSH, was decreased in 
50% of patients on dialysis and was correlated with inflammation and nutritional 
parameters (prealbumin, r = 0‟36; p = 0‟04; transferring, r = 0‟40; p = 0‟025; BMI, r = 
0‟51; p = 0‟002; arm circumference, r = 0‟65; p = 0‟000; and arm muscle 
circumference, r = 0‟72; p = 0‟000) (Fernandez-Reyes, Sanchez et al. 2009).  
The postulated mechanism for the reduction of T3 is an inhibition of hepatic type-1 
5‟-deiodinase (D1) – enzyme which facilitates the conversion of T4 to T3 and of 
reverse T3 .  to diiodothyronine (T2).  Carbohydrate deprivation has been shown to 
rapidly inhibit D1 leading to low FT3 (Katzeff, Yang et al. 1990).   
Yet, it is unclear whether these changes are due to the restriction of energy itself 
(Fontana, Klein et al. 2006) or to body fat mass changes (De Pergola, Ciampolillo et 
al. 2007).   
1.9.2 Evidence of inflammation influence on FT3 
Changes of thyroid hormones during the acute phase of disease or trauma have been 
described to be similar to those observed during starvation: serum T3 rapidly drops 
while TSH usually remains normal.  Triiodothyronine is affected within two hours of 
the onset of the acute stress (Chopra 1997).  In prolonged illness, the changes 
observed are more profound and can also affect T4 and TSH (Michalaki, Vagenakis et 
al. 2001).  
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In disease, the thyroid axis appears to be affected in two distinctive phases: receptor 
occupancy of the thyroid hormones is mainly an effect of the acute stage, whereas low 
neuroendocrine activity predominates in prolonged illness and within ICU (Wartofsky 
and Burman 1982; Chopra 1997).  
The pathogenesis is complex and several mechanisms have been implicated.  
Conversion of T4 to T3 is decreased during the acute phase of infection resulting in 
low T3 and high reverse-T3 concentrations (Jennings, Ferguson et al. 1979; Van den 
Berghe 1999).  T4 and T3 turnover is also increased during the hypermetabolic phase, 
which might contribute to low concentrations of T3 in tissue and serum (Harris, Fang 
et al. 1978).  Additionally, in non-thyroidal illness there is a failure of the normal 
negative-feedback control in the thyroid gland resulting in low TSH and, hence, low 
secretion of these two hormones (Wehmann, Gregerman et al. 1985).  Absent 
nocturnal TSH surge has been associated with non-thyroidal illness, resembling those 
changes observed in central hypothyroidism (Romijn and Wiersinga 1990); the fall in 
T3 concentration positively correlated with the loss of TSH surge in this study of 
Romijn and Wiersinga, even though the frequency of pulses was preserved.  Finally, 
altered hypothalamic-pituitary axis function is also likely to have an important role: 
post-mortem studies have shown a positive correlation between TRH mRNA in the 
paraventricular nucleus of the hypothalamus and serum T3 and TSH concentrations 
measured before death (Fliers, Guldenaar et al. 1997).  
In recent years many in vitro and animal studies have been conducted to investigate 
the role of inflammatory cytokines on thyroidal hormones.  Interleukin-1 (IL-1), 
tumour necrosis factor-alpha (TNF-a) and especially IL-6 appear to have multiple 
roles, functioning as hormones as well and regulating the acute phase response 
(Reeves and Capra) (Boelen, Maas et al. 1996).  In vivo studies have shown that IL-1, 
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IL-6 and TNF-a directly or indirectly inhibit D1 activity (Hashimoto H 1995).  As 
previously mentioned, D1 peripherally converts T4 to T3 and rT3 to T2.  IL-6 also has 
a specific role in stimulating hepatic synthesis of proteins in APR, and it has been 
postulated that one of these generated proteins could be responsible for the inhibition 
of D1 (Boelen, Maas et al. 1996).  It has also been observed that Interferon Gamma 
(IFN ) results in a dose-dependent decrease of serum
 
T4, T3 and rT3; and IL-1  
decreases liver D1 mRNA transiently.  
Studies in humans have further confirmed the findings in animal models and in vitro.  
Administration of IL-6 to healthy volunteers resulted in a decrease of T3 and increase 
of rT3, probably through inhibition of hepatic D1 activity (Torpy, Tsigos et al. 1998). 
The administration of TNF-a had a similar effect on serum T3 and rT3 (van der Poll, 
Romijn et al. 1990), even though it could also be an indirect response to the increased 
IL-6 secondary to the TNF-a.   
It is controversial whether sick euthyroid syndrome represents a physiologic response 
to illness, or if it is a maladaptative state instead (De Groot 1999).  In any case, the 
literature is abundant giving clear evidence that cytokines play a central role in the 
physiopathology of thyroid hormones during illness.  
Even more interesting, some studies has shown an independent positive association 
between low FT3 and survival of critically ill patients (Maldonado, Murata et al. 
1992). 
1.10 Glutamine 
GLN is the most abundant free amino acid in the human body (Young and Ajami 
2001).  It has been described as a „conditionally essential‟ aminoacid (Lacey JM 
1990).  Several studies have attempted to demonstrate the possible benefits of 
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supplementing this aminoacid in depleted states, but the evidence is not fully 
conclusive yet.  
Various mechanisms have been advocated for the beneficial effects reported in some 
of the articles, which include metabolic, immunologic, antioxidant, and gut protection 
(Preiser and Wernerman 2003).  GLN enhances the function of lymphocytes, 
neutrophils and monocytes (Parry-Billings, Evans et al. 1990; Ogle, Ogle et al. 1994; 
Andrews and Griffiths 2002); enhances heat shock protein synthesis – stress-inducible 
proteins which protect cells from stress and injury (Wischmeyer, Kahana et al. 2001); 
it is a precursor of glutathione (Ziegler, Rippel et al.) and hence prevents oxidative 
stress (Amores-Sanchez and Medina 1999); attenuates the production of nitric oxide 
following intestinal ischemia injury (Khogali, Pringle et al. 2002); preserves high-
energy phosphate levels and decreases lactate accumulation following endotoxemia 
(Wischmeyer PE, Singleton KD et al. 2002); and it may decrease intestinal 
permeability and preserves the gut mucosal barrier (van der Hulst, van Kreel et al. 
1993; Tremel, Kienle et al. 1994).  
1.10.1 Evidence of glutamine effect on insulin resistance 
It is well documented that tight glycaemic control in acutely ill patients reduces 
adverse outcomes and improves long-term survival (Gore and Jahoor 1994; Malmberg 
1997; van den Berghe, Wouters et al. 2001).  Thus, strict protocols have been 
introduced to ensure glycaemic control in ICU, removing any potential negative effect 
of hyperglycaemia or relative insulin deficiency.  
In dogs infused with glucagon, insulin and glucose, Borel described an increase of 
46% of glucose required to maintain euglycaemia in those that had simultaneous GLN 
administered.  This effect was due to enhanced glucose utilization caused by GLN 
 
27 
(Borel, Williams et al. 1998).  The use of this aminoacid has also been associated with 
improved insulin sensitivity in multiple-trauma (Bakalar, Duska et al. 2006) and ICU 
patients (Dechelotte, Hasselmann et al. 2006).  As consequence, a number of studies 
have been conducted to evaluate the effect of this aminoacid on the outcome of 
severely ill patients.  In a meta-analysis, GLN supplementation in surgical patients 
was associated with a reduction in infectious complications rates and shorter hospital 
stay; and in critically ill patients it was associated with reduction in complications and 
mortality rates, with the greater benefits associated in those patients receiving high 
parenteral doses (Novak, Heyland et al. 2002).  Nevertheless, it remains to be 
elucidated whether the main driver of this observed better outcome is a direct 
metabolic action of GLN or is due to the improved glycaemia and insulin resistance.  
1.10.2 Evidence of glutamine effect on proteins 
In severe illness, the release of amino acids during protein
 
breakdown in skeletal 
muscle is not in proportion to the muscle constituent
 
amino acids.  Many of these 
amino acids are converted to GLN and released from muscle to meet the demand for 
additional amino groups and for added gluconeogenesis (Griffiths RD 2001) as the 
accelerated synthesis is insufficient to maintain the intramuscular concentration of 
free GLN (Mittendorfer, Gore et al. 1999).  Nevertheless, the levels of free GLN in 
muscle rapidly falls as transport out of muscle is maintained and clearance from the 
plasma by other tissues increased, which suggests activated transport mechanisms 
(Mittendorfer, Gore et al. 1999).  As the reserves become depleted, net GLN efflux 
from skeletal muscle is maintained by decreasing the utilization rate in myocytes 
(Gore and Jahoor 1994). 
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Multiples studies have shown that GLN addition to PN formulations reduces muscle 
wasting and increases protein synthesis in the skeletal muscle (Jepson MM 1988; 
MacLennan P 1988; Stehle P 1989; Hickson, Wegrzyn et al. 1996).  Its inclusion in 
intensive care protocols has now become routine resulting in real outcome benefits 
(Preiser JC 1996). 
1.10.3 Evidence of glutamine changes during illness 
During critical illness large amounts of aminoacids are released from muscle, with 
GLN and alanine accounting for more than half (Gamrin, Essen et al. 1996).  
Nevertheless, plasma GLN concentration has been reported to fall up to 58% 
following critical illness or injury, with concentrations remaining low for over 21 
days (Planas, Schwartz et al. 1993).  
Several hypotheses have been proposed to explain the important release of this 
aminoacid following stress: GLN is a vital energy source for enterocytes – for which 
demand is markedly increased in stress, and for rapidly dividing cells such as 
macrophages and lymphocytes, and plays a determinant role in renal acid-base 
homeostasis particularly during acute illness (Newsholme, Crabtree et al. 1985; 
Wilmore 2001; Aledo 2004).  
Thus, GLN stores deplete rapidly and the production capacity of the body is 
insufficient to cover the requirements in critical illness.  As a consequence, GLN has 
been described as a „conditionally essential‟ aminoacid (Lacey JM 1990).   
Patients with moderate burn injuries have consistently shown a better survival rate 
and lower infection rate if GLN is added (Garrel, Patenaude et al. 2003).  In ICU, 
GLN concentration <0.42 mmol/L is associated with increased mortality (Oudemans-
van Straaten, Bosman et al. 2001), and GLN supplementation is associated with better 
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outcome.  These findings are consistent with other studies performed in critically ill 
patients (Griffiths, Jones et al. 1997; Houdijk, Rijnsburger et al. 1998; Hammarqvist 
1999; Goeters, Wenn et al. 2002).  Some, however, have failed to prove either benefit 
or deleterious effects after adding lesser amounts of GLN (Hall, Dobb et al. 2003), 
which suggests a dose dependent benefit (Gómez-Candela, Castillo et al. 2006).  
1.10.4 Evidence of glutamine and IGF-1 interaction 
The decreased utilization of GLN in the intestine and characteristic low IGF-1 plasma 
concentration during sepsis have been linked in various studies, suggesting that serum 
IGF-1 may have a direct effect on stimulating GLN transport across the intestinal 
mucosal barrier (Souba, Herskowitz et al. 1990; Austgen, Chen et al. 1991; Austgen, 
Chen et al. 1992).  
There are a number of articles about the effect of GH and IGF-1 in GLN metabolism.  
Jackson et al observed an increase of plasma GLN concentration in patients who had 
IGF-1, GH and GLN added to their PN formulation; however, GLN production and 
metabolic clearance rates were not altered (Jackson, Carroll et al. 2000).   
Nevertheless, the effect of parenterally administered GLN on serum IGF-1 has not yet 
been studied in human adults.   
1.11 Analytical methods 
1.11.1 IGF-1 
IGF-1 and IGF-2 circulate bound to specific proteins (IGFBPs) in plasma. There are 
seven high affinity IGFBPs described (IGFBP 1 to 7). Their role is to regulate the 
availability and bioactivity of the IGFs.  More than 90% of plasma IGF-1 is bound to 
 
30 
IGFBP-3, and less than 5% is free circulating form. The remainder of the hormone is 
bound to the other six binding proteins (Clemmons 1991).  
The affinity of IGF-1 to the binding proteins covers a large range, from the production 
of highly stable complexes to the production of labile bounds required for rapid 
hormone release in some physiological situations (Carrick F 2002).  Therefore, the 
proportion of the free circulating fraction may vary.   
Different analytical errors can occur, depending on the IGF-1 to IGFBP plasma ratio: 
 Binding proteins will predominately bind to the IGF-1 tracer in samples with 
low IGF-1, leading to an overestimation of plasma concentration.   
 However, in those specimens with high hormone concentration, predominant 
binding of IGFBP to the available IGF-1 from the sample will take place, 
leading to underestimation of IGF-1 levels.  
Therefore, direct determinations of IGF-1 can give false results due to the slow 
dissociation of the IGF-1/IGFBP complexes during incubation. 
Various techniques have been described to separate IGF-1 from its binding proteins 
(size exclusion chromatography, solid-phase extraction, acid-ethanol extraction and 
others) but they have either poor reproducibility or are very time-consuming and 
impractical for measuring a large number of specimens.  Alcohol-extraction is 
probably the commonest method, but recovery of IGF-1 bound to IGFBP is just 70-
80% due to co-precipitation, and the remaining IGFBP in the sample may still 
interfere with the assay (Daughaday WH 1980).  Therefore, the alcohol-extraction 
method gives false low results.  
In our laboratory, we have recently opted for the implementation of an IGF-1 
radioimmunoassay method – IGF-1 Mediagnost (DE/CA/40/00809/5 - Reutlingen, 
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Germany). This is based on the dissociation of the IGF-1/IGFBP complexes in an 
acidic buffer followed by addition of IGF-1 antiserum and excess of IGF-2.  The 
antiserum binds the IGF-1 present in the sample, and the IGF-2 excess forms new 
complexes with the dissociated IGFBPs.  Therefore, IGFBPs are not physically 
removed, but their reactivity, and therefore their possible interference in the assay, is 
neutralised (Figure 1.1).   
 
 
Figure 1.1: principle of the IGFBP-blocked IGF-1 radioimmunoassay  
 
Cross-reactivity between IGF-2 and IGF-1 is extremely low (<0.05%) and does not 
interfere the interaction of IGF-1 with the tracer.  These characteristics together with a 
sensitivity of 0.02 ng/L, recovery of 100% in human serum, and within-run 
coefficient of variance (Margetts, Thompson et al.) below 8% (Mediagnost 2005), 
made this method an excellent option for our study.  
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IGF-1 Mediagnost had a positive bias of 12% in the external quality control scheme 
(provided by United Kingdom National External Quality Assessment Service – UK-
NEQAS). This is affected by the dominant use of the Immulite method by its 
participants.   
1.11.2 FT3 
Only 0.3% of T3 circulates free in plasma. The remaining 99.7% forms a reversible 
bound with carrier proteins (mainly TBG, but also transthyretin, albumin and free 
fatty acids).  Dilution of samples alters the binding of carrier molecules to serum 
proteins and, therefore, disturbs the equilibrium between the free and bound hormone.  
Thus, determination of FT3 involves a significant technical challenge.  
Equilibrium dialysis and ultrafiltration are considered the gold-standard methods 
(Nomura, Sakurada et al. 1985). They physically separate the bound from the free 
fractions, allowing measurement of the latter with a sensitive immunoassay.  These 
techniques, however, are time-consuming and impractical for routine medical use.  
The development of reliable immunoassays has allowed high throughput of samples 
and fast turnaround times. The ADVIA Centaur FT3 assay is a one-step competitive 
immunoassay using direct chemiluminescent technology. It has an analytical 
sensitivity of 0.2 pg/L and interassay CV below 3.09%.  In this method, FT3 in the 
sample competes with its synthetic analog, which is covalently coupled to 
paramagnetic particles (solid phase) for a limited amount of monoclonal anti-T3 
antibodies labelled with acridinium-ester.  Labelled-antibody methods are claimed to 
be more reliable than labelled-analog assays, and less sensitive to the effect of dilution 
in the bound/free-hormone equilibrium of the sample (Burtis CA 2005).   
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External quality control – also provided by UK-NEQAS, gave excellent scores 
(A=22; B=0.1; C=1.4). 
1.12 Laboratory demand management  
The determination of biochemical analytes for diagnosis, management or monitoring 
of human diseases has undergone a profound transformation in the last three decades. 
Several thousands of years have been required to evolve from the early description of 
diabetes mellitus in the Ebers Papyrus containing remedies "to eliminate urine which 
is too plentiful" in Egypt around 1500 BC, to the manual and time-consuming 
processing of biochemistry tests developed during the last century. However, just few 
decades have been required to transform these manual techniques into highly 
automated laboratories, capable of processing dozens of thousands of tests per day.  
For example, the laboratory at Norfolk and Norwich University Hospital analyses in 
excess of 60,000 tests daily. This extraordinary change to automated laboratories has 
been possible thanks to the confluence of various factors such as the development of 
new materials, more precise instrumentation, the development of new biochemistry 
techniques, the use of molecular genetics for the production of reagents, and the 
sophistication of electronics and automation. 
The total number of staff may not have changed much in a front line laboratory today 
compared with that 30 years ago. However, the efficiency in terms of number-of-
tests/staff ratio has dramatically improved. For example, taking historical local data 
from Norfolk and Norwich University Hospital NHS Foundation Trust, the ratio 
test/staff has increased by 400 fold.  
This change does not only affect routine biochemistry, but also more specialised 
analytes such as FT3 or IGF-1.  
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1.12.1 Historical perspective  
Medical laboratories have a relatively recent history. In 1791, the physician and 
chemist Antoine François Fourcroy (1755 - 1809) was convinced that "the success of 
chemistry would one day change the face of medicine and result in a beneficial 
revolution" (Fourcroy 1801). Fourcroy proposed that a chemical laboratory should be 
set up in hospital wards. Up to then, chemical laboratories in the 17th and 18th were 
used to prepare chemical remedies rather than to carry out chemistry investigations 
with the purpose of supporting the medical care of patients. This concept was new for 
that era. He pointed out that the care of a large number of patients would bring 
practical problems, which would require the construction of chemistry laboratories 
supported with all the materials and tools required for the chemical analysis (Buttner 
1991): 
 
“Un pareil hopital devroit etre amplement foumi de tout ce qui peut servir 
I'execution de ce plan. A peu de distance d'une salle de vingt ou trente lits, 
seroit construit un laboratoire de chimie pourvu de tous les materiaux et de 
tous les ustensiles necessaires a I'analyse animale. Un grand nombre de 
thermometres comparables, de barometres, d'electrometres atmosphcrique, de 
balances de Sanctorius, pour peser les malades; un ou plusieur lits, de 
baignoires, dispose de faҁon à pouvoir etre peses commodcment; les 
machines nouvelles pour la respiration, des apparails d'eudiometrie, suivant 
les derniers principes de M. Seguin;'" en un mot tout ce que la physique 
exacte peut foumir de res.sources, des moyens et d'instrumens pour connoitre 
les phenomenes de la vie, doit etre rassemblc autour des malades." 
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He also emphasised that these assays should be performed by "physicians versed both 
in the fundamentals of modern sciences and in nosology". Here, Fourcroy signalled 
the importance of the specialisation in medical pathology.  
From 1840 several laboratories were established in Europe as in Würzburg 
Juliusspital in 1841 (de Gruyter 1983) or the General Hospital in Viena in 1844 
(Buttner and Habrich 1987).  
In the middle of the 19th century, Claude Bernard (1813 - 1878), who is considered 
by many the founder of the experimental medicine, referred to the laboratory as the 
"sanctuaries rèel" - the true sanctuary, of scientific medicine (Bernard 1865): 
 
"C‟est qu‟en effet ces procédés et ces méthodes scientifiques ne s‟apprennent 
que dans les laboratoires, quand l‟expérimentateur est aux prises avec les 
problèmes de la na-ture ; c‟est là qu‟il faut diriger d‟abord les jeunes gens ; 
l‟érudition et la critique scientifique sont le partage de l‟âge mur ; elles ne 
peuvent porter des fruits que lorsqu‟on a com-mencé à s‟initier à la science 
dans son sanctuaire réel, c‟est-à-dire dans le laboratoire." 
 
A century later Erwin Ackerknecht (1906 - 1988) differentiated between the 
"laboratory medicine" of his time in contrast to the preceding "hospital medicine" 
(Ackerknecht 1950). Clinical laboratories spread rapidly during this century.  
The development of electrical instrumentation, particularly from the beginning of the 
1900s, allowed the construction of automated systems. A small number of 
rudimentary devices were implemented during the 1930's and 1940's. The labour 
shortage caused by the First and Second World Wars in a first instance, and the 
 
36 
scientific-technical revolution during 1950-60 generated a cascade of new 
instrumentation able to process an increasing number of samples with progressively 
less manual input. This process allowed the widespread use of highly automated 
standalone analysers during 1990‟s.  
The introduction of robotics about 20 years ago marked the beginning of a new period 
for clinical laboratories. The implementation of IT integrated and fully automated 
tracked laboratories can process high number of tests with even more reduced turn-
around times.  
1.12.2 Recent changes and challenges  
In the United Kingdom, a survey of the informatics systems in the pathology services 
of the National Health Service (NHS) run by the National Health Service 
Management Executive (NHSME) in 1993 found insufficient on-line access to results 
for hospitals and primary care users. This group proposed a five years plan to provide 
results, reports and management data electronically to primary and secondary care 
users, including ordering and protocol-determined selection of investigations. The 
NHSME also highlighted the importance of other developments such as transmission 
of digital images and the application of networks for clinical problem solving 
(National Health Service Management Executive 1995).  
The NHS Audit Commission in England and Wales is responsible for overseeing the 
external audit of the NHS and also charged with reviewing the value for money 
provided. Following the publication in 1991 of The Pathology Services: A 
Management Review by this Commission (NHS Audit Commission 1991), a series of 
audits were carried out in the next years. In 1993, the communication and 
organization of NHS laboratories were audited. In this report, demand for pathology 
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services was highlighted as a key strategic element. Improved information to inform 
pathologists of patterns of request, and to inform users of how their requesting 
patterns compared with those of their peers; this strategy would allow much greater 
scope for intervention with advice and guidance (NHS Audit Commission 1991).  
1.12.2.1 Pathology demand 
The growing evidence of escalating cost of pathology services against a background 
of constrained NHS budgets was at the core of the above suggestions. The cost-
effectiveness of laboratory investigations was not determined yet, as a proportion of 
investigations might not bring real benefit to patient care, while low-requesting 
physicians might not be getting the full benefit of this service for patients. This audit 
from the Audit Commission published in 1993 summarised the different strategies 
used for this purpose in 113 different sites in England and Wales, and also proposed 
alternatives (see figure 1.2 below): 
 
o Development of computerised information systems to produce information on 
requesting patterns of users.  
o Comparison and interpretation of these patterns of use. 
o To establish regular pathology users groups in order to advise on best medical 
practice use of the service and to develop protocols for procedures to be 
followed.  
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Figure 1.2: methods used for demand management in England and Wales. Figure  
taken from Critical Path. An analysis of the Pathology Services – Audit Commission 
1993. 
 
Data collected from clinical biochemist and chemical pathologist consultants working 
in the NHS revealed that workload from primary care rose by an average of 83% 
between 2000 and 2004 (Beastall 2004). In this survey, all UK consultants based in 
biochemistry were contacted by email requesting workload information for that 
period, and a response rate of 25% was achieved.  
The workload of pathology services has been reported to increase out of proportion of 
health care activity (Smellie 2003). This same effect has been observed in Norfolk, 
where demand for laboratory tests has escalated from less than 20,000 in 1960 to 
more than 14 million expected in 2014; this has happened despite the moderate 0.74% 
population growth reported in this region.  
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Nevertheless, diagnostic pathology services must continue been delivered, in spite of 
the increment in demand and the paradoxical systematic reduction of Pathology 
funding.  
1.12.2.2 Number of tests per sample ratio 
The test-sample ratio has also progressively increased over time. In the publication of 
the DoH „Getting results: Pathology services in acute and specialist trusts‟ the 
Healthcare Commission reported the following about biochemistry requesting from 
Accident and Emergency (A&E) departments: 
“In 2002/2003 there was one biochemistry request from A&E for every 3.81 
attendances; by 2005 demand had increased to one in every 3.58 attendances. A&E 
doctors requested an average of 8.52 biochemistry tests per referral in 2005, compared 
with 7.83 in 2002/2003.” 
The introduction of profile requesting (set of investigations agreed for defined clinical 
presentations such as chest pain, abdominal pain, etc) and „organ specific‟ set of tests 
in the laboratories i.e. liver function test, renal function tests, full blood count, has 
caused the escalation of this ratio.   
1.12.2.3 General Medical Services contract 
The General Medical Services (GMS) contract was introduced in England and Wales 
in 2003 (Checkland 2004), with equivalent programs established in Scotland and 
Ireland. GMS was a contract between surgeries and primary care organisations for 
delivering primary care services to local communities. The Quality and Outcomes 
Framework (QOF) was introduced on 1st April 2004 as part of the GMS contract. 
QOF included clinical, public health, and quality and productivity domains. Primary 
care practices were financially rewarded according to their performance in each 
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domain i.e. achieving cholesterol and diabetes screening, control and monitoring 
targets. This contract had the potential to reduce inequalities in the delivery of clinical 
care, particularly in areas of deprivation (Doran, Fullwood et al. 2008). The 
implication for laboratory tests was a sudden increase of demand and significant cost 
impact, but laboratories were supposed to just assume the cost implications of those 
changes (Price and Jones 2008).   
1.12.2.4 Other causes of the swift of the NHS towards primary care  
The population is ageing, with more patients having chronic diseases and requiring 
effective long-term management. Simultaneously, factors such as social changes with 
more people living alone, increasing expectations of both patients and doctors, and the 
advent of the World Wide Web where patients have easy access to information and 
sometimes become advocates of their own medical care, have put increasing pressure 
in hospital care. The need to control costs and the concern about the appropriateness 
of medical care model in some situations where admission to hospital may not be the 
most appropriate option, has progressively shifted some areas of care of patients to 
primary NHS services (Edwards and Hensher 1998). As a consequence, in 
comparison with the total requests received in the laboratory, the number of 
biochemistry and haematology tests requests from GPs increased from 37.2% and 
25.8% respectively in 2002/2003 to 41.7% and 30.6% in 2005 (UK Healthcare 
Commission March 2007).  
The Primary Care Strategic Framework of the DoH published in 2005 – Caring for 
People Beyond Tomorrow, has consolidated this swift (Department of Health 2005). 
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1.12.2.5 Variations of demand within primary care users 
A comparative analysis in 2002 to study whether variations in pathology test 
requesting between different general practices could be accounted for by socio-
demographic or for other descriptive indicators of the practice (such as the number of 
GPs in the surgery, or the presence of a specialist mini clinic in the services provided 
in the practise) found large and significant differences in pathology tests requests. The 
population corresponded to a single district with 165,000 patients distributed in 22 
general practices. This variation was thought to result from individual variation in 
clinical practice rather than population difference (Smellie, Galloway et al. 2002).  
In another study of 229 GPs from 40 surgeries from five different areas in The 
Netherlands, involving five regional diagnostic centres, the interquartile range of 
number of tests per GP per year was 663-1500. The response to the survey was 97%. 
Lower numbers of tests ordered were associated with GPs who had been involved in 
developing guidelines, surgeries that had more than two GPs, and GPs with more than 
1 year of experience working with a problem-oriented laboratory order form 
(Verstappen, ter Riet et al. 2004). 
Figure 1.3 illustrates the variation of annual requests within a group of 24 surgeries 
(anonymised data) from the same geographical area (Norwich Clinical 
Commissioning Group). With very similar population served, there are four fold 
difference in B12 and folate requests between surgeries “D” and “T”, and between 
surgeries “J” and “K”. Marked variations can also be seen in routine haematology as 
Full Blood Count, and in the other investigations.  
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Figure 1.3: annual requests per 1000 population by Practice (Norwich CCG, 2013) 
 
Based on data from tests ordered by GPs taken from QOF returns during two weeks, 
the NHS has estimated up to 100-fold variation in request rates for some tests (The 
NHS Atlas of Variation in Healthcare, November 2011) (figures 1.4 and 1.5). A 
detailed report of the variation of laboratory investigations in primary care is in 
preparation and expected to be published soon.   
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Figure 1.4: estimated annual rates of use for 14 pathology analytes form the National 
Laboratory Medicine Catalogue. Figure taken from The NHS Atlas of Variation in 
Healthcare, November 2011. 
 
 
Figure 1.5: estimated annual rate of use of folate tests ordered by GPs per practice 
population by Primary Care Trust (PCT) in a total of 72 different PCTs, 2011. Figure 
taken from The NHS Atlas of Variation in Healthcare, November 2011. 
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1.12.2.6 Technology updates 
Pathology workload is increasing 6-10% every year (Lord Carter of Coles 2006), not 
in proportion with the growth of clinical activity. This is due to increments of both 
appropriate and inappropriate requests. The reasons behind this change can be found 
in the technical progress in laboratory medicine, which has allowed automated and 
multiple testing, and quick turnaround times. Simultaneously, research in the 
pharmaceutical industry and other sectors is constantly developing new diagnostic 
tests and also making more affordable the existing ones, which is increasing the test 
repertoire. These changes together with computerised communications have 
introduced an element of easiness in requesting tests, as users in primary and 
secondary care can now communicate with the central laboratory and have access to 
sophisticated investigations from their own desk. In addition to this, users of 
diagnostic services are more defensive in the way they request for fear of missing a 
test and the possible medico-legal consequences, which had triggered the so called 
"defensive medicine" (Tancredi and Barondess 1978; Summerton 1995; Catino and 
Celotti 2009).  
Unnecessary test repetition has been identified as a costly consequence of all the 
above (van Walraven and Raymond 2003).  
1.12.2.7 Lord Carter’s report 
In 2006 an independent review of the Department of Health was conducted (Lord 
Carter of Coles 2006). In that report, key areas for improvement in relation to the use 
of pathology services were identified: 
 There was large variation in requesting patterns in primary care. 
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 To repeat the test - incurring in extra cost, was easier than to look up an earlier 
result of the same investigation.  
 A proportion of tests requested in Primary Care were repeated unnecessarily in 
Secondary Care following the patient‟s admission to hospital.  
 High levels of unnecessary investigations were more common at night when more 
junior and less experienced physicians were generally on call.  
 The blind use of guidelines was sometimes promoting multiple and unnecessary 
testing. 
 In some cases ie. eGFR, Ca125, there was an evidence-based requirement for 
additional testing, which DOH‟s National Service Frameworks had addressed. 
However, the consequences of the changes had sometimes not been adequately 
consulted with the bodies representing the diagnostic services.      
 In some situations, there was a lack of appreciation on the part of the requesting 
clinician about the appropriateness of particular tests and the usefulness of the 
information obtained from the test result. It was thought inevitable that the 
knowledge gap between the requester and the pathologist would grow wider as 
laboratory medicine become more sophisticated. 
 This knowledge gap highlighted the clinical contribution that laboratory medicine 
could make to the treatment and care of a patient. This should be done in a context 
of dialogue between the pathologist and the clinician. This was considered 
particularly valuable at the time when the clinician was considering making a test 
request and, later on, when the result of the test was interpreted.  
In summary, and among other findings, Carter's report identified shortcomings of 
communication and insufficient use of information technology (IT) resources, which 
had led to cases of poor practise and was undermining the cost-effectiveness of 
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Pathology services for clinical care. Carter's report stressed the potential of Pathology 
services as a "powerful tool for disseminating knowledge within the NHS".  
The conclusions and recommendations of this report have marked a stepping stone in 
the changes in pathology since 2006.  
1.12.3 Impact on demand of IFG-1, FT3 and other biochemistry tests 
It would have not been possible to adapt to the enormous workload increment 
happened in the last 20 years if the technological and IT advances had not taken place. 
However, as illustrated in figure 4.1 (see Results section) the demand growth appears 
to be far from reaching the inflection point yet, despite of the different strategies 
adopted to moderate this escalation (see description of methods in figure 1.2). The 
systematic incorporation of new technologies and the update of the laboratory systems 
with more sophisticated software are allowing this constant growth.  
However, this technological revolution cannot be fully applied in all cases. The lack 
of international standards and the presence of analytical interference are still affecting 
numerous tests. In these situations, analytical assays may need to remain manually 
intensive and time consuming, such as some radioimmunoassays. This was the case of 
IGF-1 during this study as there was not an international standard and, in addition, 
IGF-1 is affected by binding proteins (IGFBP) interference which causes considerable 
disparities of results in the reports of the external quality assessment schemes. 
Therefore we opted to use the gold standard IGF-1 method as an alternative with 
sufficiently good analytical performance for medical purposes had not yet been found.  
In summary, requesting non-clinically justified investigations has detrimental effects 
on healthcare as it increases the turn around times of results; undermines the timely 
availability of results that are genuinely relevant for the clinical care of patients; 
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increases the cost of laboratory and the NHS services; puts unnecessary working 
pressure on laboratory staff; leads to avoidable further investigations and referrals; 
delays clinical decisions of physicians; and makes clinical care less cost-effective. In 
essence, unjustified requesting of laboratory tests undermines the clinical care of 
patients and goes against the principles of Good Medical Practice. Conversely, the 
under-use of certain tests leaves patients with sub-optimal management and 
potentially missed diagnosis. 
For all these reasons, laboratories must be proactive in creating instruments to help to 
rationalise the use of pathology resources, ensuring the best service for patients in an 
environment of financial constraints.  
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AIM  
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2. Aim   
Firstly, to investigate the effect of glutamine, glucose control and severity of disease 
on IGF-1 and FT3 in patients receiving parenteral nutrition. It was considered that 
understanding these effects might allow a more precise, rapid and individualised 
adjustment of the PN feeds, and could potentially reduce clinical complications and 
improve survival, particularly in critically ill patients. 
Secondly, to develop a diagnostic tool to assist with the decision making of selection 
of tests for the diagnosis and management of patients with complex diseases that 
required manual or costly laboratory investigations such as IGF-1, FT3 or other 
endocrinology tests.  
 
52 
 
 
53 
METHODS 
 
54 
 
55 
3. Methods 
3.1 Recruitment of patients 
Approval of the study was granted by ethics and research committees.  Local research 
approval was obtained from the Research Department at Sheffield Teaching Hospitals 
NHS Foundation Trust.  
TPN was prescribed to patients who were malnourished or at risk of malnutrition 
patients if they had:  
 inadequate or unsafe oral and/or enteral nutritional intake 
 non-functional, inaccessible or perforated (leaking) gastrointestinal tract.  
A patient was classified as malnourished if he had had unintentional weight loss 
greater than 10% within the last 3–6 months. 
A patient was considered to be at risk of malnutrition in the presence of any of the 
following: 
 have eaten little or nothing for more than 5 days and/or are likely to eat little 
or nothing for the next 5 days or longer. 
 have a poor absorptive capacity, and/or have high nutrient losses and/or have 
increased nutritional needs from causes such as catabolism.  
All patients starting PN at the Royal Hallamshire Hospital were eligible for inclusion 
in this study. PN was prescribed when indicated according to NICE and BAPEN 
guidelines and the Protocols of the STH (Sheffield Teaching Hospitals NHS 
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Foundation Trust) Nutrition Support Team. Patients were transferred to enteral or oral 
feeding as soon as possible.  All patients were informed about the study, provided 
with the Information Sheet, and asked to give consent to the additional measurements 
required for the study.  Patients who were unable to consent for themselves (patients 
on ITU who were unconscious, severely ill, or with a terminal illness), a family 
member, partner, close friend or attorney acting under a Lasting Power of Attorney 
(Personal Consultee) was approached for an opinion, which was documented. If no 
relative or friend was available, the person responsible for the care of the patient 
(excluding those involved in running this study) was approached and the decision 
documented. 
At the end of the study a total of 56 patients were recruited.  
3.2 Nutritional requirements 
Estimations of nutritional needs were based on the Schofield equation (Schofield 
1985) as shown in chart 3.1 below. Adjustment for activity was estimated to be 
between 1.0 - 1.2 of the calculated BMR in line to Elia reports (Elia 2005). A 
correction factor for stress factors and body temperature was applied as indicated in 
chart 3.2 
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Age 
(years) 
Males  Females 
18-29 
BMR = 15.057 x (wt kg) + 692.2 SEE = 
153 
BMR = 14.818 x (wt kg)  + 
486.6  
SEE = 119 
30-59 
BMR = 11.472 x (wt kg) + 873.1  
SEE = 167 
BMR = 8.126 x (wt kg)  + 
845.6  
SEE = 111 
≥ 60 
BMR =11.711 x (wt kg)  + 587.7 
SEE = 164 
BMR =9.082 x (wt kg)  + 
658.5 
SEE: 108 
SEE = Standard error of estimation 
Chart 3.1: Schofield equation adjusted to gender and age for the calculation of the 
nutritional requirements. 
 
 
CLÍNICAL STATUS  CORRECTION FACTOR 
Surgical intervention            1.1-1.2  
Infectious disease 1.2-1.6  
Sepsis, acute pancreatitis …………       1.4-1.8  
Tª > 38ºC  .…….1,13 per ºC above 37ºC  ……    
 
Chart 3.2: stress and body temperature correction factors. 
 
3.2 Parenteral nutrition feeds 
 
We used Nutriflex (B. Braun Melsungen AG, Melsungen, Germany) and Oliclinomel 
(Baxter, Deerfield, Illinois, US) commercial PN feeds.  Non-standard bags (made 
using individual constituents provided by Baxter) were prepared for patients on ICU 
in order to allow us to optimise nutrition or to make restrictive alterations on 
electrolytes.   
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All preparations included a concentrate of trace elements (Chauhan, Lebeaux et al.) 
and water and fat soluble multivitamins (Cernevit), both supplied by Baxter (Baxter, 
Deerfield, Illinois, US).   
Glutamine was administered as a standard daily dose per patient of 20 g of Dipeptiven 
(Fresenius Kabi AG, Bad Homburg, Hesse, Germany) in a separate intravenous 
infusion or pooled with the feed in the PN bag. It was given to all patients on 
ICU/SHDU/NITU; to those in whom indication for PN was a primary gastrointestinal 
illness; and if the protein requirements were not covered with the content of proteins 
available in the PN bag. Glutamine provided 20 g of N(2)-l-alanyl-l-glutamine 
(13.46 g of L-glutamine, 8.2 g of L-alanine) in 100 millilitres.  
Management of patients was based on joint decisions of the Nutrition Support Team 
(chemical pathologist, dietician, pharmacist and TPN specialist nurse).  
Sample 1 (or baseline) reflected the status of patients who were not receiving 
parenteral nutrition.   
Parenteral nutrition was administered via a dedicated peripherally inserted central 
catheter (PICC) or a dedicated centrally placed central venous catheter, and 
introduced progressively starting at no more than 50% of estimated needs for the first 
48 hours. It was withdrawn once adequate oral or enteral nutrition was tolerated and 
nutritional status was stable. 
After collection of this first specimen, PN was progressively introduced at no more 
than 50% of estimated needs for the first 24 to 48 hours following NICE guidelines 
recommendations (National Collaborating Centre for Acute Care 2006) and current 
RHH practice.  Adjustment to patients‟ requirements was made on the basis of their 
body mass index (BMI), weight loss, previous nutritional intake, and serum 
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concentration of potassium, phosphate and magnesium.  Schofield‟s equation was 
used for the calculation of Estimated Energy Requirements (Houdijk, Rijnsburger et 
al.), and calculated stress factors were adopted to adjust for illness.  Energy and 
protein content was increased as tolerated in critical care patients but generally only 
reached approximately two thirds of the calculated requirements whilst the patients 
remained on ICU. 
PN was withdrawn as soon as the requirements were met via enteral route, provided 
there was no evidence of malabsorption.   
3.3 Biochemistry and categorization of patients  
A baseline specimen and two weekly samples for two weeks thereafter were collected 
in each patient. Days of collection of specimens were converted into categories 1 to 5: 
day 0, days 1 to 3, days 4 to 7, days 8 to 11, and days 13 to 14 respectively.  
Routine laboratory measurements, including U&E, LFTs, calcium, phosphate, 
magnesium, glucose and CRP (as recommended by NICE) were be measured before 
starting parenteral nutrition and at least twice a week thereafter. Ward-based glucose 
monitoring (Abbot Optium Xceed glucose meter) was arranged as indicated at the 
discretion of the project investigator and director, who were also responsible for 
prescriptions of parenteral feeds using the existing protocols. Feeds used, insulin 
requirements, glycaemic control, complications and nutrient intake by all routes were 
recorded as per current routine practice. 
Patients were categorised on the basis of glycaemic control (mean blood glucose 4-7 
mmol/l, 7-10 mmol/l and >10 mmol/l), use of GLN or not, and severity of illness 
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(intensive care versus general surgical wards). Intensive care units included ICU, 
Surgical High Dependency Unit (SHDU) and Neuro ICU (NICU).  
IGF-1 and Free T3 were the final outcome measurements. They were quantified on all 
five specimens (assuming survival, or not discharged) whether the patient continued 
on parenteral nutrition, transferred to enteral/oral nutrition or had to discontinue 
nutrition support because of a complication.  
3.4 Specimen collection  
Lithium heparin coated tubes and silica coated tubes with a polymer gel for serum 
separation (BD Vacutainer, Franklin Lakes, NewJersey, US) were used for collection 
of specimens.  Tubes with lithium are used for routine biochemistry requests on ICU, 
while silica tubes are more common in other hospital wards.   
All samples were centrifuged, the serum separated in plastic tubes and kept at -20 
degrees centigrade until assay.  
3.5 Apparatus 
Analyses of IGF-1 were performed using Mediagnost IGF-1 radioimmunoassay 
(DE/CA/40/00809/5 - Reutlingen, Germany). The radioactivity was determined in a 
well-autogamma scintillation counter (Berthold DPC Gamma-C12 multicrystal 
gamma counter, Berthold, Wilberg, Germany) with compatible assay calculator for 
Windows (Biosoft AssayZap, Cambridge, UK).  
FT3 measurements were performed using an Advia Centaur XP Immunoassay System 
analyser (Siemens Healthcare Diagnostics, Deerfield, Illinois, US).  
 
61 
Glucose and CRP were assayed in Beckman Coulter Synchron LX20 Pro analysers 
equipped with a Near-infrared Particle Immunoassay Detection System (Beckman 
Coulter Inc, Fullerton, California, US).  
Ultra pure reverse osmosis water was obtained using Synchron system (Beckman 
Coulter Inc, Fullerton, California, US) and this was used to prepare all solutions and 
to rinse materials.  
Other equipment utilised included: Incold –20°C freezer in which samples were 
stored until analysis, Spiramix 10 roller mixer and VM20 vortex mixer, Corning 4010 
multi-tube vortexer, and Spinchron DLX centrifuge. Dilutions and additions of 
samples and reagents were performed with Pipetman and Finnpipette pipettes.  
3.6 Materials and reagents 
3.6.1 IGF-1  
Materials provided by Mediagnost were stored at four degrees centigrade, and 
included anti-rabbit-IgG biotin-conjugated antibody (capture antibody), anti-rabbit-
hIGF-1 recombinant antibody (specific antibody), IGF-1 labelled with radionuclide I-
125, standards, control, assay buffer, acidification buffer, dilution buffer, and 
streptavidin coated tubes. IGF-1 Mediagnost is a manual radioimmunoassay. The 
preparation of the samples, analyses and quality controls were preformed by the 
principal investigator.  
10ml non-coated plastic tubes (Sarstedt, Beaumont Leys, Leicester, UK) were used 
for sample storage.  
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3.6.1.1 Calibration and control preparation 
A five-point calibration was prepared with standards also provided by Mediagnost. 
A lyophilized control from the manufacture‟s kit was reconstituted with deionised 
water. Additionally, high and low IGF-1 concentration in-house controls were 
prepared by pooling and aliquoting patients‟ samples.  
3.6.2 FT3 
Reagents obtained from Beckman (Beckman Coulter Inc, Fullerton, California, US) 
were stored at four degrees centigrade. They included acridinium labelled monoclonal 
mouse anti-T3 antibodies, and a T3 analogue covalently coupled to paramagnetic 
particles. Beckman FT3 is an automated immunoassay. Preparation of the samples for 
analysis and data collection was done by the principal investigator.  
3.6.2.1 Calibration and control preparation 
Two-point calibration was prepared with Beckman standards.   
Liquichek Immunoassay Plus Control was used as controls (Bio-Rad Laboratories, 
Hercules, California, US). 
3.7 Demand management  
3.7.1 Auditing the total number and the incremental rate of tests requests  
We quantified the growth of test requests in our hospital from 1955 to 2014 to 
evaluate the extent of this problem in this trust.  
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Simultaneously, we wanted to estimate the potential savings from avoiding clinically 
unnecessary testing. For this, the minimum requesting times for various tests and for 
sets of tests were agreed after internal discussion, and we estimated how many test 
would be saved should these intervals be applied. 
3.7.2 Evaluation of the requirements of laboratory users 
A meeting was organised with users of biochemistry services. As there are many 
medical specialties in the trust, a subgroup of main users was selected. These included 
the following: 
1. Endocrinology 
2. Medicine For the Elderly  
3. Renal Medicine  
4. General Practitioner 
5. Chemical Pathology, who chaired the meeting. 
At this meeting, the purpose of the project was explained, detailing that the aim of this 
change was to assist doctors in the diagnosis and management of patients by using 
biochemistry algorithms. These flowcharts would be accessible for either primary 
care only, secondary care or both, depending on the specific case. Examples of this 
were given i.e. patients with hyponatraemia are, generally, poorly investigated (and 
managed) by hospital juniors; however, low sodium is a very rare presentation in 
Primary Care, and it is virtually always caused by drugs, so GPs would not find very 
useful that the laboratory provides them with a complex algorithm and investigative 
protocol. On the other side, it is not unusual that patients present with endocrine 
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disorders in Primary Care, but the biochemical investigations that they require are 
probably different from Secondary Care – ie. 21-OH progesterone.  
It was agreed to trial a small number of algorithms initially, which was settled on a 
hirsutism flowchart aimed at GPs. 
At the meeting also was agreed a list of most useful flowcharts to develop: 
 Hirsutism 
 Erectile dysfunction 
 Gynaeomastia 
 Menopause 
3.7.3 Information to colleagues 
As most algorithms involve endocrine disorders and would require discussion and 
agreement with them, I prepared a presentation to communicate the details of the 
project to consultants, junior doctors and specialist nurses. Opportunity was given to 
ask and discuss possible concerns.  
Emphasis was given on the opportunities offered by the implementation of this project 
beyond cost-savings i.e. education, communication, patients‟ experience and care.  
3.7.4 Algorithms discussed and agreed with relevant teams 
A draft for the laboratory investigation of hirsutism in primary care was produced.  
The design of the algorithm implied that users were guided through sequential 
questions and options which opened specific screens. At the end of this process, an 
individualised managerial decision was suggested depending on the answers provided 
for each particular clinical case. This answer could range from either the 
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recommendation of the necessary investigations required to reach a diagnosis, to the 
advice of referring the patient to the appropriate specialist service, or the suggestion 
that no further investigations were required and discharge might be appropriate.  
A separate meeting was held with one of the endocrinologist who was particularly 
interested in this project. The agreed final draft was emailed for feedback to all 
consultants in the Endocrinology department.  
This process (preparation of the draft, agreement with the lead endocrinologist and, 
finally, discussion with the endocrinology department) was replicated for all other 
algorithms developed during this study.  
3.7.5 Implementation: IT challenge and learning process 
The project was discussed with the IT Pathology manager, and an implementation 
plan was designed.  
The software used by the NNUH was WebICE (WebICE, 2100 RiverEdge Parkway, 
Suite 500, Atlanta, GA 30328).  
There was no previous experience in the design of algorithms using this software. 
Therefore, it was required liaison with the WebICE provider and the NNUH IT senior 
manager. The implementation required successful communication between WebICE 
and the interface and software used for the analysers in the laboratory.  
Hirsutism was used as a prototype because it was a basic algorithm which was 
considered suitable to test the capability of the software.  
In a second stage, if the implementation of hirsutism were successful, the algorithm of 
erectile dysfunction was planned to be the next one to be tried. Erectile dysfunction 
had a complex design and, as such, would test the full potential of the system. 
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3.7.6 Communication with users and feedback  
Doctors from Primary and Secondary Care have been involved in this process.  
The availability of this tool was communicated to all NNUH pathology users through: 
 The Pathology Users Group meeting – this is a committee aimed to promote 
the communication between Pathology services and its users. It meets 
quarterly and is integrated by delegates of primary care and secondary care 
specialties, in addition to pathology seniors.  
 Communication sent to the Local Medical Committee. 
 Letter in the communications circular distributed to medical surgeries and 
edited at NNUH (appendix, figure 3.1).  
 Informative comments included in the report of the biochemistry results. 
These comments were added whenever the clinical details suggested that the 
patient was been investigated for one of the conditions included in this project 
(see examples of interpretative comments in appendix, figure 3.2).  
As mentioned before, a talk was given to senior and junior endocrinologists, and 
specialist nurses in endocrinology.   
After the system had been introduced and run, a questionnaire was sent electronically 
to all GPs.  
3.8 Statistical analysis  
Opinion from the STH Statistics Service was obtained for the design and analysis of 
the data.   
SAS Statistics software and a Mixed Linear Model were used for the statistical 
analysis of IGF-1 and FT3 results (SAS Institute Inc., Cary, NC 27513-2414, USA).  
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We had to use this unusual regression-type analysis which allowed to account for the 
fact that we had longitudinal data with categorical and continuous values. 
Microsoft Office Excel was used for graphs and calculations of demand management 
data. 
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RESULTS 
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4. Results  
4.1 IGF-1 and FT3   
All 58 patients who started TPN were eligible for the study. Only two cases refused 
consent and were not included in the research.  Patients 31 and 37 were excluded 
from the analysis as they had no input data in one of the categories (Glucose), which 
made them invalid for the Mixed Linear Model statistical analysis used. 
Specimens were collected, and the days of collection were converted into categories 1 
to 5 (defined as Day_Group category): day 0, days 1 to 3, days 4 to 7, days 8 to 11, 
and days 13 to 14 respectively.  
TPN was stopped in 29 patients before completion of the two weeks of enrolment in 
the project. The commonest cause was reintroduction of enteral feed and/or discharge 
(Graph 4.1).  
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10  Switch to enteral feed
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 Catheter-related sepsis
 Sepsis from other
source
 Catheter-related
phlebitis
 Catheter fell out
 TPN continued
 
Graph 4.1: causes which led to stopping TPN within the two weeks study. It also 
includes a category for those patients who continued on TPN until completion of the 
study. 
 
Out of the 54 recruits, 23 had all five samples taken and 31 had less than five.  The 
most frequent causes for this were discontinuation of TPN (and therefore, less 
frequent biochemical monitoring) and hospital discharge (table 4.1). In total, 222 out 
of the maximum 270 possible specimens were collected. Quartiles of the total number 
of days on PN are shown in graph 4.2.   
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 Cause 
Number of patients 
 Discharged 12 
 TPN discontinued 8 
 Death 9 
 Sample not collected 1 
 Insufficient sample volume  1 
 
Table 4.1:  Number of patients who had less than five samples collected, and cause. 
 
 
 
Graph 4.2: Quartiles of the number of days the patients remained on PN during the 
period of the study. 
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The distribution of patients within the hospital wards was approximately equal: 26 
cases were treated in medical or surgical wards, and 28 in intensive care units (ICU, 
SHDU and NICU). The primary diagnosis of the patients were as seen in table 4.2 
below:  
 
 
 
 
 
 
 
 
 
 
 
Table 4.2: Percentage of primary diagnosis of patients requiring TPN at the Royal 
Hallamshire Hospital.  
 
 
Some of the bags were standardised from the provider but others were individualised 
to the specific needs of the patient. The nitrogen, carbohydrates and lipids content of 
the bags, as well as the non-protein kilocalories to nitrogen ratios are shown in the 
table 4.3 
 
 
 
 
Disease Percentage 
Cancer Bowel 13 
  Other 30 
Surgical Not cancer 
Gastro-
intestinal 
13 
  Obesity 9 
  Other 5 
Medical Pancreatitis 13 
  Other 18 
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Nitrogen 
Carbohydrates 
(Kcal) 
Lipids             
(Kcal) 
Kcal Total 
Ratio 
Kcal/N2 
Range 5.7 - 15,49 300 - 1000 0 - 1000  795 - 2000 74 - 222 
Median  12,1 600 500 1100 107 
Table 4.3: content of nitrogen, carbohydrates, lipids and non-protein kilocalories-to-
nitrogen ratios of the TPN bags provided. 
  
Intravenous GLN was administered for 24 hours prior to sample collection in 85 
specimens out of the 222 collected. Overall, 41 patients were given GLN at some 
time during parenteral nutrition. 
A glucose result was not available in all the specimens collected as it was not 
routinely requested once TPN ceased.  Table 4.4 illustrates the patients categorised on 
the basis of glycaemic control.  It is relevant of note that all patients were routinely 
started on an insulin sliding scale in the intensive care units; also those in other 
hospital wards were prescribed intravenous insulin whenever glucose control was 
suboptimal. Consequently, the distribution of glucose results within the three 
categories is uneven.  
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Glucose result 
 Corresponding 
glucose category 
 Number of samples 
 4-7 mmol/l 1 151 
 7-10 mmol/l 2 46 
 >10 mmol/l 3 3 
 
Table 4.4: Number of samples in each category of serum glucose. 
 
The overall results can be seen in table 4.7 in the appendix. 
Evaluation of the data was complex. A Mixed Linear Model was used.  This is 
a regression-type study that allows the analysis of longitudinal data (samples 
taken sequentially in time) with categorical and continuous values. 
The analyses started by fitting the covariance structure for IGF-1 and FT3 to the 
repeated measurements. This accounted for the fact that a patient's measurements, 
across their 5 samples, were related to each other. A number of different plausible 
covariance structures were considered and the 'best' was selected using Akaike's 
Information Criterion (AIC) which assessed the fit of the models, whilst penalising 
models with more parameters (see appendix, tables 4.8 and 4.9). The analysis of the 
outcome measures (IGF-1 and FT3) consisted in a series of steps for which a number 
of assumptions within this Mixed Linear model were selected: Compound Symmetry 
assumed that observations on the same patient had homogeneous covariance and 
variance; Autoregressive Structure assumed that covariances between observations on 
the same patient decreased with time (i.e. visits further apart were less correlated); 
Spatial Power Structure was a generalisation of the Autoregressive structure, which 
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again assumed that measurements further apart were less correlated, but using the 
separation in days rather than sample collection number; Heterogeneous was selected 
as the variances of the measures on different visits were different; Random Patient 
Effect included a common contribution to the covariances between observations, 
because they were made on the same patient. 
Tables 4.10 and 4.11 (appendix) illustrate the significance of the different variables in 
the first step to the fixed model. In this preliminary evaluation, the day the samples 
were collected and the location of patients (ICU vs other hospital wards) had the 
lowest p value – statistically more significant, for both IGF-1 and FT3.  
Tables 4.14 and 4.15 (appendix) show the estimate of each effect on IGF-1 and FT3 
in relation to the reference category (estimate zero).  
For IGF-1, a Heterogeneous First-Order Autoregressive structure was selected – 
lowest AIC (see table 4.8). This structure modelled different variances for the 
observations on different samples (1 to 5) and let measurements on visits further apart 
be less correlated. 
For FT3, a First-Order Autoregressive with Random Patient structure was selected 
(see table 4.9). Again this structure let measurements on visits further apart be less 
correlated, but also included a common contribution to the covariances between 
observations, because they were made on the same patient. 
After finding an appropriate covariance structure, the next step was to consider the 
fixed effects, i.e. ITU versus Ward, GLN or not, Glucose Group, CRP and Day 
Group. An ANOVA approach (using Kenward-Roger degrees of freedom) was used 
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to test whether these variables of interest had a significant effect on the outcome. The 
variable with the largest p-value was 'dropped' from the model, and the model was re-
fitted, step-by-step, until only significant terms remained.  
Ward location and Day of Collection of samples were the two variables with 
statistical significant effect on both IGF-1 and FT3 (tables 4.12 and 4.13). The final 
results for these two variables on the mixed model can be seen in tables 4.5 and 4.6 
below.  
Patients on ICU, SHDU and NICU had higher IGF-1 and FT3 than those on other 
hospital wards (p = 0.0053 and p = 0.0446 respectively).  IGF-1 and FT3 were also 
progressively higher from sample 1 to 5 (p = <0.0001). Detailed estimates of these 
effects are illustrated in tables 4.14 and 4.15 (appendix).  
 
Effect on 
IGF-1 
Num 
DF 
Den 
DF 
F 
Value Pr > F 
ICU_Ward 1 51 8.49 0.0053 
Day_Group 4 42.1 7.84 <.0001 
 
Table 4.5: Final Mixed Model on IGF-1. ANOVA Fixed Effects. 
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Effect on 
FT3 
Num 
DF 
Den 
DF 
F 
Value Pr > F 
ICU_Ward 1 54.5 4.23 0.0446 
Day_Group 4 84 13.83 <.0001 
 
Table 4.6: Final Mixed Model on FT3. ANOVA Fixed Effects. 
 
 
The mean values of IGF-1 and FT3 for “ICU_Ward” and “Day_Group” effects are 
shown in Tables 4.16 and 4.17 respectively (appendix).  These results are absolute 
estimates from patients number 1 to 56 (excluding 31 and 37).   
Plotted mean values showed a linear increase from sample 1 to 5 (graphs 4.3 and 4.4).  
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Graph 4.3: IGF-1 mean values for all specimens collected. 
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Graph 4.5: FT3 mean values for all specimens collected. 
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4.1.1 Subgroup of patients who reverted to enteral nutrition 
20 patients stopped TPN and reverted to enteral nutrition before the 14
th
 day of the 
study.   
In this subset of patients, we re-named the specimens in order to observe how IGF-1 
and FT3 was affected after TPN was discontinued.  For this purpose, sample 1 was 
defined as the sample taken the last day a patient was on TPN (whenever it was 
within the 14 days period of the study).  The next sample was named sample 2, and so 
on with the subsequent specimens.  Therefore, all patients were on enteral nutrition 
from sample 2 onwards. 
In contrary to the linear increase of IGF-1 observed in graph 4.3 and 4.4 for all 54 
patients, IGF-1 mean values fell after stopping TPN [t (17) = 2.47, p<0.05] (Graph 
4.7). This drop continued in sample 3 (collected between days 4 and 7).  Sample 4, 
however, had again a marked increase of the hormone.  
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Each patient had a total of five specimens collected for this study and, therefore, the 
number of samples taken after TPN was stopped depended on how soon they reverted 
to enteral feed.  Consequently, in graph 4.7 there are no results for day 5 – as none of 
the patients were on enteral feed on days 1 and 2 of the study, and only five results 
were available for day 4 – only five patients reverted to enteral feed before the third 
sample of the study was collected.  
Graph 4.8 depicts the plot of FT3 mean values of the samples of patients who 
reverted to enteral nutrition. They are also arranged from 1 to 4 counting from the 
specimen collected the last day patients were on TPN.  In contrary to what is 
observed for IGF-1, FT3 is not affected by interruption of TPN in this subgroup of 
patients.   
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Graph 4.7: IGF-1 mean values after enteral feed was re-introduced. Sample 1 is the 
specimen taken the last day TPN was given. Samples 2, 3 and 4 correspond to the 2
nd
, 
3
rd
 and 4
th
 specimens collected for this study after the TPN was discontinued.  
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Graph 4.8: FT3 mean values after enteral feed was re-introduced. Sample 1 is the 
specimen taken the last day TPN was given. Samples 2, 3 and 4 correspond to the 2
nd
, 
3
rd
 and 4
th
 specimens collected for this study after the TPN was discontinued. 
 
4.1.2 Subgroup of patients who developed sepsis during PN 
Six patients developed sepsis during TPN.  Intravenous nutrition was not 
discontinued in two of them as the central line was clearly not the source of the 
infection.  The central vein access device was the source of the infection in only one 
case.   
As in the previous subgroup, we re-named the samples in order to compare how IGF-
1 and FT3 was affected after the episode of sepsis.  Thus, sample 1 was defined as the 
specimen taken the day before the onset of sepsis – whenever sepsis happened within 
the 14 days of the study. Subsequent specimens were named sample 2, 3 and 4.  
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IGF-1 serum concentration dropped in the first sample collected after the onset of 
sepsis in all specimens (Graph 4.9).  Graph 4.10 illustrates the plot of IGF-1 mean 
values from samples 1 to 4. 
FT3 serum concentration in samples 1 and 2, and FT3 mean values in samples 1 to 4 
are shown in Graphs 4.11 and 4.12 respectively.  FT3 did not show a consistent 
pattern of change after sepsis: five samples had lower concentration of the hormone 
while it was higher in the other two.   
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Graph 4.9: IGF-1 concentration of the samples collected before and after the onset of 
sepsis (samples 1 and 2). 
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Graph 4.10: IGF-1 mean values of the samples collected from the onset of sepsis. 
Sample 1 corresponds to the specimen taken just before the onset. 
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Graph 4.11: FT3 concentration of the samples collected before and after the onset of 
sepsis (samples 1 and 2). 
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Graph 4.12: FT3 mean values of the samples collected from the onset of sepsis. 
Sample 1 corresponds to the specimen taken just before the onset. 
 
4.2 Demand management  
4.2.1 Number of tests requests at NNUH 
The total number of annual tests requested from 1955 to 2014 at the NNUH are 
summarised in the Figure 4.1. We observed a progressive increase year after year, at 
an annual rate between 5-10%. In 1955, around 11,000 biochemistry investigations 
were requested, while in the year 2000 more than 4,100,000 were requested, and 
more than 14,000,000 are expected in 2014. As illustrated in the chart below, these 
increments have been progressively bigger.  
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Figure 4.1: biochemistry tests per year at NNUH from 1957 to 2014 (it does not 
include haematology, microbiology or other laboratory specialties). 
 
We estimated that if CRP were requested no more frequently than once every 48 
hours, it would save 33,088 tests per year at NNUH.  LFTs requested at a maximum 
of twice per week (with a safety system in place to allow extra requests in exceptions 
such as liver failure) would reduce the number of requests by 13,728 annually. 
Review of the B-ALP isoenzymes requested in 30 consecutive days evidenced that 
70% of requests were not clinically indicated or had insufficient clinical or 
biochemical information to justify the test. 
It was calculated that savings from only CRP reagents – overheads not included – 
would amount £19,219 (€23,063) per year in this laboratory.  
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4.2.2 Algorithms  
Four algorithms were completed and fully implemented:  
 Hirsutism (appendix, figure 4.2) 
 Erectile dysfunction (appendix, figure 4.3), with additional information edited 
next to the flowchart (appendix, figure 4.4). 
 Gynaecomastia (appendix, figure 4.5).  
 Menopause (appendix, figure 4.6). 
Hirsutism was first tested in the “trial” area of WebICE. After this period, the access 
was open to all users. The algorithm of erectile dysfunction was developed soon after.   
Agreement of each flowchart required a series of meetings with the secondary care 
teams affected. Apart from endocrinologists, general surgeons were involved in the 
final discussion of gynaecomastia, and gynaecologists participated in the final version 
of menopause.  
Galactorrhoea has already been designed and agreed, and is in process of final 
implementation by the IT laboratory manager (appendix, figure 4.7) 
A multidisciplinary group with special interest in obesity has recently been set up in 
Norfolk. This group is integrated by primary care physicians who are particularly 
interested in obesity, endocrinologists, public health medicine specialists, hospital 
specialist nurses and community nurses. The algorithm for obesity in adults is 
currently under discussion. The draft can be seen in Appendix (figure 4.8). 
Management of obesity in children is currently under discussion with the 
paediatricians. The draft is available in Appendix (figure 4.9).  
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The algorithm for oligo-amenorrhoea (figure 4.10) in primary care is under 
development.  
Other algorithms were also considered. However, considerations with the relevant 
secondary teams evidenced them non viable. For example, an algorithm for abnormal 
liver function tests were produced and agreed with hepatologists, radiologists, 
virologists and microbiologists (figure 4.11). However, the estimated number of 
additional new referrals to the hepatology service due to the implementation of this 
change was considered beyond the capability of this specialist service.  
The conversion of the algorithms into an effective software tool for users required 
writing them in an understandable language for IT specialists who had no clinical 
background. For this I prepared Power Point documents with a detailed step by step 
description of each flowchart. The details of these documents can be seen in the 
appendix in figures 4.12.1 to 4.12.4. 
4.2.3 Feedback from users  
A survey was sent 12 months after the implementation of the algorithms. The 
questions posed and the feedback from users are shown in figure 4.13 in the 
appendix.  
A total of 117 users answered the survey, 28.8% of which had already used this tool. 
51.3% were aware of the algorithms. 77.1% believed it is a useful tool for patients‟ 
care, with 21.9% not having an opinion formed yet, and one user who believed is was 
not useful for patients‟ care. Most of those 77.1% who believed it is useful, thought 
the algorithms make easier to request the necessary investigations (86.9%). Two users 
believed algorithms make managerial decisions more difficult. Avoidance of 
unnecessary blood tests, which improves patients‟ care, and also avoidance of 
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preventable appointments by requesting all relevant investigations in the first visit 
were the two main advantages of this tool, with 85.1% and 84.0% respectively. 86.1% 
believed this tool should continue and developed; 0% believed it should not continue; 
and 13.8% had no opinion yet.  
Two thirds said they would recommend the use of this tool in primary care, one user 
said he would not, and one third had no formed opinion yet.   
The four most popular algorithms suggested to develop were anorexia, dementia, 
abnormal LFTs and subfertility.  
4.2.4 Other results 
1. The Departments of Clinical Biochemistry and Endocrinology have collaborated 
reviewing the available guidance and local practise with the aim to determine the key 
tests to confirm or refute common endocrine disorders. This collaboration was part of 
a wider project in the Department of Endocrinology.  The study concluded that 
performing investigations prior to new patient appointments reduced delays prior to 
diagnosis.  
2. The GPs have expressed their interest in extending the range of “one click” test 
profiles. These are agreed investigations for specific clinical situations that are 
requested by selecting a specific test profile instead of having to select all the tests 
required one by one. There are numerous examples where this could be applicable, 
such as in most pre-clinic appointments. This is a very simplified version of the above 
algorithms, but is proving very successful among primary and secondary care users. 
There are ongoing discussions with representants from the Clinical Commissioning 
Groups (CCG) who in turn get feedback from the GPs of the area they cover.  
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5. Discussion 
The validity of the interpretation of results is highly dependant on the standardization 
of the processes involved in the research.  
Apart from analytical standardization (see section 1.5 Analytical methods), research 
in nutrition involves specific standardization issues: basal energy expenditure which 
varies depending on factors such as body composition, height, age, circulating 
thyroxine, environmental temperature and stress; level of activity of patients; 
different metabolic states such as hypermetabolism during illness or trauma; 
absorptive capacity of the gut which is affected by integrity of the intestinal mucosa, 
length of the intestine, production of enzymes, etc (Cunningham 1980; Schutz, 
Acheson et al. 1985; Staal-van den Brekel, Dentener et al. 1995; Johnstone, Murison 
et al. 2005; Utaka, Avesani et al. 2005). 
Additionally, healthy subjects show a large inter-individual weight gain response to 
overfeeding, suggesting that there are also significant differences in the capacity to 
regulate energy expenditure and metabolic efficiency (Joosen and Westerterp 2006). 
It implies that, even though formula estimations of nutritional requirements have been 
validated for the general population, they might not be fully valid when applied to 
specific individuals.  Therefore, even though the TPN feeds where prescribed 
according to the calculated requirements in our research, the response of the patients 
to these feeds might have been different.  
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5.1 Parenteral nutrition 
5.1.1 Administration of TPN  
Administration of PN resulted in a mean increase in IGF-1 by 15 µg/L (p<0.01) in 
each sample with respect to the previous one.  Previous published reports had 
suggested a role of IGF-1 in nutrition (Ketelslegers, Maiter et al. 1995), but our 
findings provide evidence that IGF-1 is responsive to administration of PN.  The 
increase of IGF-1 mean values was approximately linear as seen in graph 4.3.  
FT3 mean serum concentration increased 0.36 pmol/L (p<0.001) after PN was 
initiated.  A plot of mean values can be seen in graphs 4.5 and 4.6.   
Studies in animals have shown that FT3 decreases during food deprivation (Messer, 
Johnson et al. 1995; Kmiec, Kotlarz et al. 1996; Christensen, Malinowski et al. 1997). 
These results have been confirmed in humans (Kaptein, Fisler et al. 1985; Fontana, 
Klein et al. 2006).   
However, data on the response of FT3 to refeeding is scarce.  The time reported for 
FT3 to return to the base levels varies from 24 hours to more than three days 
depending on the study (Hugues, Burger et al. 1984; Messer, Johnson et al. 1995).  
The central point of this discrepancy is that fasting periods and sampling times after 
refeeding vary in the different studies and are usually short.   
The recovery of the thyroid axis appears to be multifactorial as it has also been 
associated with cytokines and down-regulation of T3 genes in response to fasting 
(Feelders, Swaak et al. 1999; Faggioni, Moser et al. 2000; Boelen, Wiersinga et al. 
2008).  Hence, the time required for its recovery after fasting has not yet been 
clarified.   
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In previous studies, it is possible that timing of specimen collection after refeeding 
was not sufficiently long to detect increases in this hormone.  Additionally, previous 
publications were based on short starvation periods which might not adequately 
represent our group of patients.  Christensen and Kmiec observed prompt recovery of 
FT3 serum levels after 14 and 48 hours of food deprivation respectively (Kmiec, 
Kotlarz et al. 1996; Christensen, Malinowski et al. 1997).  In Messer‟s experiment 
however, starvation lasted four days, but he did not measure FT3 beyond 72 hours 
after refeeding (Messer, Johnson et al. 1995).  Thus, the results of these authors are 
probably of limited applicability to our group of patients as it is not uncommon that 
patients are started on PN after they have been deprived of enteral intake for more 
than five days (depending on the primary pathology and the reason for hospital 
admission).   
In our research, we have analysed FT3 for two weeks in 54 patients after starting PN, 
which represents the highest number of participants and longest observation time to 
date.  Our results provide strong evidence that FT3 is positively affected by PN.  
Another unexpected finding from the analysis of our data was the drop of IGF-1 after 
discontinuing PN (graphs 4.9 and 4.10).  This is the first time that such an effect has 
been described.  We suspect it might relate to the incomplete normalization of either 
the absorptive intestinal competence or the metabolic processing of macronutrients 
after reintroduction of enteral feeding.   
NICE guidelines make clear recommendations on PN initiation, but they are not 
specific about how to discontinue PN.  Previous research about transition from PN to 
enteral feed has only focused on the potential risk of developing hypoglycaemia, 
demonstrating that tapering PN is not required for its prevention (Krzywda, Andris et 
 
96 
al. 1993; Eisenberg, Gianino et al. 1995).  Based on this premise, the abrupt 
discontinuation of PN is not uncommon once enteral nutrition has been initiated.  
In our research, however, IGF-1 and FT3 reflect more profound metabolic changes, 
suggesting that re-adaptation to the enteral route is not immediate.  According to our 
results, intestinal absorption may take around seven days to be fully functional – even 
after short periods of absence of intestinal mechanical stimulation from food.  
If these results and proposed hypothesis are confirmed, the current common practice 
for transition from PN to enteral nutrition would require reconsideration.   
5.1.2 Effect of sepsis 
The adverse effect of inflammation on IGF-1 has previously been reported (Ross R 
1991; Mesotten and Van den Berghe 2006).  In all the patients who developed sepsis 
in our study (seven cases), IGF-1 fell by between 5.2% and 40.6% in the first 
specimen collected after its onset.   
Sepsis caused more variable changes in FT3 concentration.  A reduction of between 
5.1% and 30.7% was observed in five cases, but FT3 remained stable in one patient, 
and increased in the remaining one.  
5.1.3 Patients’ location – Intensive care units vs other hospital wards 
Malnutrition has been associated with higher incidence of post-operative 
complications and longer recovery time, which increases in patients‟ morbidity and 
mortality (McWhirter and Pennington 1994; Potter, Langhorne et al. 1998).  
Paradoxically, underfeeding patients on ICU has been associated with more survival 
rate (Krishnan, Parce et al. 2003) and, therefore, this practice is increasingly being 
recommended (Patino, de Pimiento et al. 1999; Jeejeebhoy 2004).  In addition to this, 
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acute illness causes increase cytokines production, which in turn inhibits IGF-1 
(Hawker, Stewart et al. 1987; Ross R 1991; Wojnar, Fan et al. 1995; Cotterill, 
Mendel et al. 1996) and FT3 synthesis.  Therefore, we categorised patients on the 
basis of their location in the hospital (acute wards vs all other wards) as nutritional 
needs are different in patients on ICU and patients with severe illnesses were more 
likely to have lower end-point markers (IGF-1 and FT3).  
Based on previous publications, we expected to detect lower IGF-1 values in 
ICU/SHDU/NITU (Hawker, Stewart et al. 1987; Ross R 1991; Wojnar, Fan et al. 
1995; Cotterill, Mendel et al. 1996).  However, we found that, on average, IGF-1 was 
27 µg/L higher (p<0.01) than in other hospital wards.  
A possible explanation for these results is that patients on ICU/SHDU/NITU 
commonly start PN feeding earlier than those on other hospital wards. Thus, 
starvation periods are less prolonged, which would result in higher baseline IGF-1 
serum concentration.   
Additionally, in all previous publications, IGF-1 concentration of the population 
studied was compared with either control healthy volunteers (Ross R 1991; Wojnar, 
Fan et al. 1995), or with IGF-1 levels in the same individuals before elective surgery 
(Cotterill, Mendel et al. 1996), or with the population reference range (Hawker, 
Stewart et al. 1987).  In our research however, we compared acutely ill patients with 
another group of hospitalised patients who were, supposedly, less acutely ill.  Thus, 
our project design is not equivalent to previous studies, and our results are not 
comparable with them. Additionally, there were only a small number of participants 
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in earlier studies (Cotterill included twelve cases, Hawker studied twenty, Ross only 
six and Wojna nine) which could have affected the power of their statistical analysis.   
FT3 was 0.44 pmol/L lower in ICU/SHDU/NITU patients (p=0.04).  This result was 
consistent with the reported effect of trauma or acute phase of the disease on FT3.  
5.1.4 Intravenous glutamine  
Some researches have previously postulated that IGF-1 serum concentration might be 
positively affected by administration of GLN.  This is based on: 
1. GLN stimulates enterocytes DNA synthesis (Rhoads, Argenzio et al. 1997). 
2. Ma et al demonstrated in rats that, after surgical stress, the dipeptide GLN-
alanine enhances gut growth and improves gut mucosa integrity and barrier 
function, in part by means of stimulating mucosal IGF-I mRNA (Ma, Jiang et 
al. 1995).   
3. IGF-1 and GLN have synergic effect on ileal adaptation (Ziegler, Mantell et 
al. 1996). 
In our study, however, we found that IGF-1 was 13.2 µg/L lower (p=0.11) in samples 
collected from patients who were on intravenous GLN.   
We found only one article about the effect of intravenous GLN on IGF-1 in humans 
(Akobeng, Clayton et al. 2002). In this research, GLN supplementation was not 
associated with any significant alteration of IGF-1 after four weeks of nutrition 
support in 15 children with Crohn‟s disease.  
In rats, Johnson demonstrated that serum concentration of IGF-1 lowered while 
glutathione (Ziegler, Rippel et al.) increased when GLN was given orally (Johnson, 
Kaufmann et al. 2003).  GSH is a tripeptide composed of 7-glutamic acid, cysteine 
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and glycine.  It is a substrate for GSH peroxidise and GSH S-transferases, and 
participates in microsomal peroxidase and radical scavenging reactions (Stadtman 
1980; Reddy, Tu et al. 1981; Burk 1983).  Therefore, it is a molecule with an 
important role in detoxification reactions.  The concentration of GSH is particularly 
high in the liver and intestine (Kosower and Kosower 1978), but levels fall 
appreciably following a short period of starvation (Jaeschke and Wendel 1985).  Cho 
demonstrated that GSH status is sensitive to amino acids supply (1981) and, thus, his 
finding was consistent with Johnson‟s more recent description of higher GSH levels 
in GLN oral supplementation.  There is evidence that IGF-1 decreases the production 
of free radicals and reactive oxidative species (ROS) (Eisner, Criollo et al. 2006; Pi, 
Goldenthal et al. 2007).  Thus, it could be hypothesised that IGF-1 may also cause an 
indirect decrease of GSH – low ROS down-regulates the promoter of the γ-
glutamylcysteine synthetase heavy chain subunit which is a key regulator of GSH 
synthesis (Day, Suzuki et al. 2003).  Similarly, as GSH conjugation is a major route 
for IGF-1 excretion, the hypothesis that high GSH levels reduce serum IGF-1 
concentration is likely.  This scenario would fit Johnson‟s description of GSH 
reduction and IGF-1 increase in GLN supplementation, and would also be consistent 
with our results.  A diagram of these relationships is illustrated in figure 5.1.  
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Figure 5.1: diagram of interaction between GLN, GSH and IGF-1 (Incr=Increase; 
Decr=Decrease; GLN=Glutamine; GSH=Glutathione; ROS=Reactive Oxidative 
Species). 
 
Studies about the effect of GLN on thyroid function are very scarce and, indeed, we 
have only found one reference.  This article described a non-significant elevated FT3 
serum concentration after starting PN in a group of nineteen acutely ill patients, but 
the FT3 level was lower in those who had additional GLN supplemented compared to 
those who only had standard PN (Carroll, Jackson et al. 2004).  
In our study we found that FT3 was 0.09 pmol/L lower in those patients who had 
glutamine added to their PN.  This difference, however, was not statistically 
significant.   
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Therefore, with the current evidence, it cannot be concluded whether addition of GLN 
affects FT3.  
5.1.5 Glucose control. 
Adequate glucose control results in a 50% reduction in mortality among other clinical 
benefits in patients on ICU.  Thus, strict glycaemic control is current best practice in 
severely ill patients.  As a consequence, the distribution of samples in the “Glucose” 
category was uneven, with the majority of cases (154) falling in category 1 (glucose = 
4-7 mmol/L) and 46 in category 2 (glucose =7-10 mmol/L).  We did not compare the 
results obtained in the third category (glucose >10 mmol/L) with the other groups as 
it only contained three specimens.  
IGF-1 enhances intracellular glucose transport and mitochondrial activity (Russo, 
Kobayashi et al. 2004).  However, research about the effect of glucose on IGF-1 have 
shown contradictory outcomes: exposure to high glucose concentrations decreased 
the release of IGF-1 in human neuroblast long-term cell cultures (Giannini, Benvenuti 
et al. 2008), whilst glucose stimulated expression of the IGF-1 gene in cultured 
glioma cells (Straus and Burke 1995).  
In our research, IGF-1 serum concentration in category 2 samples was 2.5 ug/L 
(p=NS) lower than those in category 1 (lower glucose).  It is relevant to note that 
previous studies have been carried out in vitro, which may not fully replicate in vivo 
conditions.   
Again in our study, FT3 was 0.1 pmol/L (p=NS) lower in those with worse glucose 
control.  Previously, McDonald showed that iodine uptake by the thyroid gland was 
reduced in rats following a high carbohydrate diet (Macdonald 1989); and in diabetic 
patients, various authors have reported lower circulating TSH, FT3 and FT4 
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(Ohyama, Aono et al. 1984; Proces, Delgrange et al. 2001).  Therefore, even though 
FT3 increases absorption and use of glucose in myocytes and enterocytes (Van den 
Berghe 1999), high glucose levels appear to have the reverse effect on FT3.  The 
mechanism of this effect has not been clarified yet.  
5.2 Demand management  
Effective management of laboratory demand has become a need in pathology, but 
also a challenge. Ian Barnes, former National Clinical Director of Pathology in 
England, emphasised that a minimum of 20% efficiency savings were required in 
Pathology. This target was in line with the conclusions and recommendations of Lord 
Carter‟s review (Lord Carter of Coles 2006).  
The traditional strategies adopted by laboratories to reduce workload –teaching to 
juniors, meetings with doctors, distribution of information, elaboration of guidelines 
and protocols, regular audits– have not only failed to revert the trend of demand but 
even to moderate its unrelenting growth.    
In addition to this, inequality in pathology use as seen in figures 1.3, 1.4 and 1.5 may 
cause that less resources are spent in areas with populations with greater needs, whilst 
more resources may be used in areas with less health needs.   
The NHS, as launched in 1948, was based on three principles, which are also 
included in the latest version of the NHS Constitution: to meet the needs of every 
citizen, to be free at point of delivery, and to be based on clinical need and not ability 
to pay (The NHS Constitution 2013) . Therefore, apart from the extra cost attached to 
managing resources inefficiently, inequity in the use of health resources will 
undermine the core of the NHS, and also other national health systems based on 
similar principles.  
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The escalation of demand together with the evidence of marked geographical 
variation in the use of healthcare resources despite the implementation of “routine” 
measures has put Demand Management to the front line of the agenda of pathology 
laboratories.  
After money, time is possibly the scarcest resource in the NHS. The availability of 
software to facilitate decision taking has been very well received in the local meetings 
organised with our users ie. Pathology Users Committee meetings, educational 
sessions with GPs, and meetings with CCGs representatives.  
Some UK providers have developed websites with laboratory information: 
http://www.pathology.leedsth.nhs.uk/dnn_bilm/  
http://www.labtestsonline.org.uk/  
http://www.assayfinder.com/  
 
These sites offer very valuable information about availability of clinical 
investigations, usefulness of the tests, requirements for collecting samples, etc.  
In our project we have taken a step further by not only providing information but by 
adapting that information to the needs of users. To our knowledge, this is the first 
interactive diagnostic IT tool developed for users in Primary and Secondary Care in 
the NHS.  
The implementation of this tool throughout the NHS would: 
• Avoid unnecessary blood tests, which would improve patients‟ satisfaction 
and quality of care. 
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• Optimise patients‟ appointments in primary care – all the relevant 
investigations are ordered in the first visit, avoiding preventable appointments.  
• Rationalise the use of referrals to Secondary Care i.e. avoidance of 
unnecessary referrals, insufficient Pathology investigations prior to the 
appointment, etc. 
• Harmonise the geographical variation of the use of laboratory resources. 
• Improve the overall patients‟ health care experience.  
• Quick and easy access to state of the art laboratory investigations of specific 
conditions.  
• Education: provide learning and teaching tools.  
• Strengthen the links between Primary Care, Pathology and Secondary Care, 
with the development of new and better communication channels.   
• Savings could be made in biochemical investigations by optimising the cost of 
the overall diagnostic process of patients, which can significantly contribute 
towards the aimed 20% efficiency savings. 
• It will facilitate to respond to future healthcare demands and the change of 
working practices by the optimal utilisation of technology, i.e. new laboratory 
investigations (and possibly expensive) will be included in these algorithms 
only if recommended by the appropriate bodies (NICE, etc), therefore 
avoiding inappropriate requesting.  
Nationally there is no indication that that the economic perspectives will improve to 
the point of modifying the direction of budget restrictions currently undergone in 
national healthcare. With this background and future perspective, NHS services are 
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doing their utmost to improve efficiency, and also providers will be willing to 
implement tools that facilitate this process.  
For the reasons highlighted above I believe this innovation will be very attractive to 
adopt and use by both Primary and secondary Care users, and also by other 
organisations and healthcare professionals.  
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LIMITATIONS OF THE STUDY 
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6. Limitations of the study 
1. We did not collect data about the duration of poor enteral intake or the 
nutritional status of the patients prior to PN initiation, which could have had 
an effect on the baseline IGF-1 and FT3 results.  
2. It has previously been reported that the primary disease may affect the 
response to PN (Gomez, McAlindon et al. 2008).  We did not assess the 
possible effect of this variable in our study.   
3. The final-outcome measures (IGF-1 and FT3) were determined in all 
specimens.  Some PN markers (glucose and others) were occasionally missed.  
This led to the exclusion of patients 31 and 37 from the analysis of the data.  
4. For the reason highlighted in the previous paragraph, the distribution of 
specimens in “Glucose” category was uneven, which might have affected the 
statistical analysis of the data.  
5. All ICU/SHDU/NITU patients were given GLN (Dipeptiven) together with 
PN following current best practice RHH protocols.  However, in the other 
hospital wards, GLN was prescribed depending on protein requirements, 
primary disease and severity of illness of patients.  
We found that patients on ICU/SHDU/NITU had significantly higher IGF-1 
and lower FT3 serum concentrations, but we do not know the role – if any, of 
GLN on these changes.  
6. It was not possible to evaluate the true cost-effectiveness of the algorithms as 
our IT system did not allow auditing the number of requests. However, the 
elevated popularity of the tool among primary care users – as evidenced by 
the survey, strongly suggests that this system is efficient. 
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7. Dissemination of the diagnostic algorithms in other Trusts may be limited by 
the software used in the local laboratory, and the existing IT communication 
between the laboratory of the hospital and primary care. 
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POSSIBLE AREAS FOR FUTURE RESEARCH 
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7. Possible areas for future research 
We designed this research as a pilot project aiming to determine specific areas of 
future interest.  Our results have shown that IGF-1 and FT3 drastically drop after 
discontinuing PN despite having all the requirements met via enteral route.  Further 
studies, with precise measurements of enteral intakes, are necessary to assess the 
reproducibility of our results.  Our research suggests that re-adaptation to enteral 
nutrition is progressive and may take around a week.  Therefore, it opens the 
possibility of routine use of FT3 and IGF-1 as a measure of metabolic fitness of the 
enteral route.  This could open additional research areas about enteral and metabolic 
adaptation to refeeding.  
Our results have also shown a consistent increase of IGF-1 in all patients on PN, 
which was particularly marked in those cases on ICU/SHDU/NITU.  However, we 
cannot conclude how relevant the addition of GLN was to the higher concentrations 
observed in ICU/SHDU/NITU, as all patients in this group had Dipeptiven added to 
the feeds.  The next logical step would be a trial with the addition or not of GLN to 
patients on ICU/SHDU/NITU and the other hospital wards.  However, the inclusion 
of ICU/SHDU/NITU patients in this trial would be unethical as there is proven 
evidence of the survival benefits of GLN administration in their feeds.   
Patients on ICU were, on average, less than a week on PN.  Therefore, it would be 
interesting to investigate the daily variations of IGF-1 in the first seven days after PN 
is commenced.  This might give more insight about the possible use of this marker in 
severely ill patients.  
The implemented interactive algorithms for laboratory diagnosis have been very well 
received among primary care users. They have almost unanimously expressed their 
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interest in further developing this tool. The feedback in our survey has highlighted 
anorexia, infertility and dementia as the next most useful algorithms to elaborate.  
We believe that the implementation of this is tool can contribute to rationalise the 
demand of laboratory investigations in healthcare.  
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8. Conclusions  
1. The administration of PN resulted in a mean increase between samples of 15 µg/L 
for IGF-1, and of 0.36 pmol/L for FT3, indicating that serum concentration of IGF-1 
and FT3 are sensitive markers that respond predictably to the initiation of PN in both 
ICU and non-ICU hospital wards, 
2. However, discontinuation of PN has a negative effect on IGF-1 concentration 
despite a normalized enteral intake.  
3. New onset of sepsis caused a significant fall of IFG-1 while on PN.   
4. Measurements of IGF-1 and FT3 may be useful in the optimization of nutrition 
support in the Intensive Care Unit.  To verify this, a randomised double blind trial is 
needed. 
5. There has been a systematic and persistent increase of 5-10 % during the last 60 
years in demands of biochemistry tests such as IGF-1and FT3 in Norfolk and 
Norwich University Hospital.  
6. Limiting the maximum number of CRP tests to one per 48 hours makes important 
savings at Norfolk and Norwich Hospital, showing that the rationalization of 
biochemistry tests requesting has a marked impact in the budget of pathology 
services. 
7. The use of diagnostic algorithms in medical care has excellent acceptance among 
healthcare professionals. Primary care physicians perceive this tool as an instrument 
to reduce the number of blood tests, reducing the number of unnecessary and 
preventable patients‟ appointments, improving the quality of care of patients and the 
overall patients‟ healthcare experience, and minimising the escalating cost of 
biochemical investigations. 
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Conclusiones 
1. La administración de NP causó un aumento promedio de IGF-1 de 15 µg/L, y de 
FT3 de 0,36 pmol/L, indicando que las concentraciones séricas de IGF-1 y FT3 son 
marcadores sensibles que responden de manera predecible a la NP en los pacientes 
hospitalizados, tanto en UCI como en pacientes fuera de la misma.  
2. Sin embargo, la suspensión de la NP tiene un efecto negativo en la concentración 
de IGF-1 a pesar de la normalización de la ingesta oral/enteral. 
3. La aparición de sepsis durante la administración de NP provocó una caída 
significativa de los niveles plasmáticos de IFG-1. 
4. La cuantificación sérica de IGF-1 y FT3 pueden ser de utilidad clínica para 
optimizar el soporte nutricional de pacientes en UCI. Esto requerirá verificación con 
un estudio clínico randomizado.  
5. La demanda de tests bioquímicos tales como IGF-1 y FT3 se ha incrementado entre 
el 5-10% anual durante los últimos 60 años en  Norfolk and Norwich University 
Hospital. 
6. La limitación a un máximo de un test de proteína C reactiva cada 48 horas 
supondría un ahorro considerable en nuestro centro, demostrándose que la 
racionalización del uso de pruebas bioquímicas de diagnóstico tiene un impacto 
importante en el presupuesto de los servicios de patología. 
7. El uso de algoritmos de diagnóstico tiene una excelente aceptación entre los 
profesionales de la salud. Los clínicos perciben a esta herramienta como un 
instrumento muy útil para optimizar el número de pruebas analíticas tanto para el 
diagnóstico como para el seguimiento de pacientes; para reducir el número de citas 
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innecesarias y evitables; para incrementar la calidad de la atención a los pacientes, así 
como para disminuir el coste cada vez mayor de las investigaciones bioquímicas. 
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9. Appendix 
 
Figure 3.1: letter with the notification of the implementation of the algorithms, 
distributed to users in primary care. 
 
Dear colleague,    
    Re: Laboratory Diagnosis Aid Tool 
In the last few months, we have developed a Laboratory Diagnosis Aid Tool in 
Clinical Biochemistry with the close collaboration of a multidisciplinary team of 
medical colleagues.  
This is a tool integrated on ICE Desktop aimed to support users in the Laboratory 
investigation of patients who present with complex, but not uncommon, symptoms.  
It will be accessible through an additional tag called “Conditions and Diseases” 
displayed in the site main page. This tag will give access to:  
1. Specific symptoms which will open an interactive flow chart. The 
biochemical tests required and the appropriate managerial decision to be taken 
will be displayed according to the options selected.  
2. Link to documents to access additional information i.e. differential diagnosis, 
drug interactions, a full view of the decision flow chart.  
3. Web resources such as Endobible.  
The laboratory diagnosis and management of Erectile dysfunction and Hirsutism in 
Primary Care will be available at this initial stage. These has been discussed and 
agreed with the Endocrine Team of the NNUH. We are currently working on 
gynecomastia, infertility, dyspnoea, obesity and amenorrhoea diagnosis.   
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We would like to collect as much feedback as possible as to make of this a useful tool 
for you. Please do not hesitate to contact us on the email below if you have a 
suggestion.  
Best wishes, 
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Figure 3.2: Examples of interpretative comments. 
 
Example 1: A laboratory diagnosis aid tool for erectile dysfunction is now available 
on ICE-Desktop: follow "GP profiles” tab.  Drugs causing erectile dysfunction 
include Cimetidine, Spironolactone, Oestrogens, alcohol, Methyldopa, Thiazides, 
beta blockers.  
 
Example 2: A laboratory diagnosis aid tool for gynaecomastia is now available on 
ICE-Desktop: follow "GP profiles” tab.  After idiopathic, drugs is the commonest 
cause (Digoxin, Ranitidine, Spironolactone, Enalapril, tricyclics, Methadone, 
cannabis, Finasteride, Griseofulvin, Ciproterone, Reserpine, Isoniazid, etc). Other 
causes include low testosterone, increased oestrogens (hCG producing tumours, 
chronic liver disease, malnutrition, adrenal tumors), renal failure, hyperthyroidism.  
 
Example 3: A laboratory diagnosis aid tool for hirsutism is now available on ICE-
Desktop: follow "GP profiles” tab.  Causes of hirsutism include PCOS, CAH, 
cushing‟s, adrenal or ovarian tumours. Exclude drugs (progestagens, Danazol, 
Phenytoin, Cyclosporine, Diazoxine).  
 
Example 4: A laboratory diagnosis aid tool for menopause is now available on ICE-
Desktop: follow "GP profiles” tab.  Note only FSH is required for menopause 
confirmation.  
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Figure 4.2: algorithm for the investigation of hirsutism in primary care. 
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Figure 4.3: algorithm for the investigation of erectile dysfunction in primary care.  
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Figure 4.4: additional information to the algorithm for the investigation of erectile 
dysfunction in primary care. 
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Figure 4.5: algorithm for the investigation of gynaecomastia in primary care. 
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Figure 4.6: algorithm for the investigation of menopause in primary care. 
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Figure 4.7: algorithm for the investigation of galactorrhoea in primary care. 
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Figure 4.8: algorithm for the investigation of obesity in adults in primary care (two 
pages). 
 
 
 
 
 Continue next page 
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Figure 4.9: algorithm for the investigation of obesity in children in primary care. 
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Figure 4.10: algorithm for the investigation of oligo-menorrhoea in primary care. 
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Figure 4.11: algorithm for the investigation of abnormal liver function tests in 
primary care. 
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Figure 4.12.1: document prepared for the IT manager with the explanation of the 
algorithm for the laboratory investigation of erectile dysfunction in primary care 
(screens 1 to 10). 
 
 
 
 
 
Screen 1 
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If  “YES”  in screen 2: 
 
 
 
 
 
 
 
 
 
        
Can/Does the patient achieve an erection during sleep, in the early morning, 
during masturbation or with other partners? 
 
No 
 
Yes 
 
Psychogenic causes of ED are a diagnosis of exclusion. Do 
you want to continue with further investigations? 
 
No 
 
Yes 
 
Screen 2 
Screen 3 
Comment: if NO is 
answered, then go back to 
the initial screen 
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If  “YES”  in screen 3: 
 
 
□ U&E 
□ LFTs 
□ fasting glucose 
□ lipids 
□ TFTs 
□ LH 
□ FSH  
□ testosterone  
□ prolactin 
 
 
 
 
 
All the above investigations are required. If abnormal, then consider appropriate 
referral.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screen 4 
Select all Deselect all 
EndoBible Click here for additional help or information 
 
141 
 
 
 
If  “NO”  in screen 2: 
 
 
 
Screen 5 
Possible drug effect? Exclude spironolactone, thiazides, Beta 
Blockers. * See extended list of drugs below.  
Yes 
 
No 
 
* Oestrogens, anti-androgen e.g. cyproterone, dopamine antagonists, cimetidine, 
fibrates, alcohol, guanethidine, methyldopa, clonidine, disopyramide, soja milk.  
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If  “YES”  in screen 5:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If  “Medication change not possible”  in screen 6, then go to screen 4. 
 
 
 
 
 
 
Screen 6 
Consider stopping/change medication and re-evaluate? 
Medication change 
not possible 
 
ED persists after 
medication change 
 
Screen 7 
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If  “ED persists after medication change”  in screen 6:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If  “NO”  in screen 8, then go to screen 4.  
 
 
 
 
 
 
Screen 8 
Does the patient have any condition that may lead to erectile dysfunction?: 
diabetes mellitus, hyperprolactinaemia, chronic renal failure, liver disease, 
disseminated malignancy, Peyronie disease, thyroid disease, spinal cord 
damage (MS, surgery, trauma) 
No 
 
Yes 
 
Screen 9 
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If  “YES”  in screen 8:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screen 10 
Consider specific referral if required.  
Resolution of symptoms will likely depend on causal 
treatment.  
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Figure 4.12.2: document prepared for the IT manager with the explanation of the 
algorithm for the laboratory investigation of gynaecomastia in primary care (screens 1 to 
4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screen 1 
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If “Adolescent or associated with pubertal delay” selected in screen 2: 
 
 
 
 
  
 
Screen 2 
Adolescent or associated 
with pubertal delay 
Adult 
Screen 3 
Gynaecomastia is part of 
normal development in 50-
60% of adolescent males 
and usually regresses 
within 6-18months. 
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If “Adult” selected in Screen 2: 
 
 
 
 
 
 
 
 
 
 
 
□ LFTs 
□ Prolactin 
□ Testosterone  
□ TSH 
 
 
 
 
 
 
 
Screen 4 
Possible drug effect? Drugs causing gynecomastia include oestrogens, androgens, anti-
androgens such as cyproterone, digoxin, cannabis, methadone, diamorphine, spironolactone, 
cimetidine, alcohol. 
If normal results: more information 
Select all Deselect all 
Click here for additional help or information EndoBible 
If abnormal results: more information 
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If “If normal results…” selected, then a pop up box will open with: 
 
 
 
 
 
 
 
 
 
 
If “If abnormal results…” selected, then a pop up box will open with: 
 
 
 
Trial of drug cessation if suspected drug 
effect - dependant on clinical situation. 
 
If trial not possible  
or  
gynecomastia not resolved 
then 
surgical referral may be appropriate  
Refer for appropriate investigation. 
  
If Testosterone low or Prolactin high 
refer to endocrinology 
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Figure 4.12.3: document prepared for the IT manager with the explanation of the algorithm 
for the laboratory investigation of oligo-amenorrhoea in primary care (screens 1 and 2). 
 
 
 
 
Screen 1 
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Female patient with secondary amenorrhoea and vasomotor symptoms 
(last menstrual period >12 months ago) 
 
FSH 
 
Screen 2 
Interpretation:  
FSH > 30 IU/L: Menopause CONFIRMED 
 
FSH < 30 IU/L: Menopause not confirmed. Consider other causes of amenorrhoea e.g. 
pregnancy, progesterone only pill use, PCOS, secondary hypogonadism. Consider 
endocrinology referral.  
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Figure 4.12.4: document prepared for the IT manager with the explanation of the algorithm 
for the laboratory investigation of erectile dysfunction in galactorrhoea in primary care 
(screens 1 to 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screen 1 
Galactorrhoea - defined as milk production more than one 
year after weaning or in any nulligravid woman, or any milk production in males. 
Important components of the medical history include: 
 Take drug history and exclude likely drug cause – see list here. 
 Bilateral or unilateral? Unilateral is more indicative of breast pathology; 
bilateral is more consistent with hyperprolactinaemia). 
 Reproductive history (recent pregnancy, menstrual history). 
 Neurologic symptoms, such as headache and visual field defects. 
 Medical/surgical history. 
Palpable breast mass? 
 
Yes 
 
No 
 
Link to 
flowchart 
document 
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If  “YES”  in screen 1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screen 2 
Evaluate independently. 
Surgical referral might be 
indicated. 
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If  “NO”  in screen 1:  
 
 
□ Prolactin 
□ hCG if female 
 
 
Interpretation:  
 If Prolactin elevated and patient not pregnant refer to Endocrinology.  
 If Prolactin normal, advise to avoid nipple stimulation, and re-assess if 
problem persists. 
 
 
 
 
 
 
 
 
Screen 3 
Click here for additional information 
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Figure 4.13: results of the survey sent to GPs to evaluate users’ satisfaction. 
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Table 4.7 (see next page): Results from patients 1 to 56. Classification of categories: 
ITU/Ward (ITU = 1; Ward = 2); TPN (not given = 0; given = 1); Glutamine (not given = 0; 
given = 1); Glucose Group (blood glucose 4-7 mmol/l = 1; 7-10 mmol/l = 2; >10 mmol/l = 
3).  
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Patient 
ITU / 
Ward 
IGF-1 
(ug/L)       
sample 1 
IGF-1 
(ug/L)                 
sample 2 
IGF-1         
(ug/L)       
sample 3 
IGF-1            
(ug/L)       
sample 4 
IGF-1          
(ug/L)       
sample 5 
FT3        
(pmol/L) 
sample 1 
FT3         
(pmol/L) 
sample 2 
FT3          
(pmol/L) 
sample 3 
FT3         
(pmol/L) 
sample 4 
FT3            
(pmol/L) 
sample 5 
1 2 88 85 133 159 205 3.7 3.5 4.3 4.5 3.5 
2 2 45 65 129   119 2.6 2.6 3.3   4.1 
3 2 18 21 20     2.3 2.8 4.0     
4 2 67 111 72 36 31 2.9 4.3 3.7 4.2 4.8 
5 1 65 90 39 31 72 3.0 2.8 2.6 2.8 3.2 
6 2 24 47 59 42   1.9 1.2 2.9 2.2   
7 2   14 18 28     3.1 4.4 4.1   
8 2 55 71 78 87 63 3.7 3.1 3.3 3.5 3.8 
9 2 30 46 42 63 75 2.8 2.6 2.9 3.1 3.4 
10 1 114 124 131     2.8 2.9 5.0     
11 1 90 105 110     3.6 3.5 4.4     
12 1 49 70 77 123 94 2.4 3.2 2.7 3.1 3.5 
13 1 118 73 187 213 216 2.7 2.1 2.6 4.8 4.5 
14 1 24 28 42 63 66 0.1 0.0 0.2 0.2 0.0 
15 2 39 56 84 73   2.8 3.2 3.3 3.7   
16 1 76 104 167   123 3.7 4.9 4.8   4.5 
17 2 60 104 104 108 114 4.0 4.2 5.1 5.0 4.9 
18 1 60 51       3.4 3.7       
19 1 89 105 96 50 79 1.8 2.2 3.2 3.6 4.5 
20 2 42 45 76 74   3.9 4.2 5.6 5.2   
21 1 58 91 80 101   2.2 2.5 3.2 3.1   
22 1 24 27       3.7 2.9       
23 1 59 89 103 135 118 1.1 1.1 3.3 3.0 2.7 
24 1 53 71 123 116 97 3.1 3.5 4.1 3.9 4.3 
25 2 25 36 74 29 37 1.9 3.1 3.1 2.6 3.3 
26 2 28 45 64 89 107 3.5 4.0 4.2 5.0 5.6 
27 2 20 37 50 74   1.8 2.4 2.6 3.3   
28 1 56 43 123 153   2.9 1.4 2.7 4.2   
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Patient 
ITU / 
Ward 
IGF-1        
(ug/L)       
sample 1 
IGF-1      
(ug/L)       
sample 2 
IGF-1         
(ug/L)       
sample 3 
IGF-1            
(ug/L)                
sample 4 
IGF-1          
(ug/L)                
sample 5 
FT3        
(pmol/L) 
sample 1 
FT3         
(pmol/L) 
sample 2 
FT3          
(pmol/L) 
sample 3 
FT3         
(pmol/L) 
sample 4 
FT3            
(pmol/L) 
sample 5 
29 1 82 78 79     2.2 3.2 2.8     
30 2   63 79 68 72   2.6 3.2 3.0 2.7 
31 2 33 52       3.1 2.8       
32 1 37 120 156 76   1.3 2.4 2.6 2.3   
33 2   58 83       2.2 3.9     
34 2   46 52 65     3.1 2.6 2.8   
35 1 144 125 155 262 360 2.5 2.6 3.6 5.1 5.5 
36 1 70 95 82     3.7 3.8 4.7     
37 2 27 39 77   106 2.5 3.1 4.5   4.2 
38 2 29 33 46 35 28 3.7 4.0 4.4 3.6 4.5 
39 1 66 91 131 85 58 2.4 2.5 2.5 2.8 2.9 
40 1 50 53 47 73 81 2.2 2.7 2.7 2.8 3.1 
41 2 64 65 111     3.8 3.9 3.9     
42 2 31 47 54 110   1.7 1.7 2.7 4.9   
43 1 96 63 100 105   3.1 2.6 3.2 3.1   
44 1 102 61 113 168 157 3.1 2.2 3.7 4.3 4.0 
45 2 110 158 124 177 163 3.5 3.7 4.0 4.4 6.0 
46 2 95 113 144     4.6 4.6 5.1     
47 1 96 120 117 141 157 2.1 3.4 4.5 3.6 4.2 
48 1 136 138 148 133 140 2.8 2.7 3.3 3.7 4.1 
49 1 38 90 81 49   4.2 2.5 3.9 4.6   
50 2 113 102 148 177 119 3.7 4.5 3.8 3.5 3.8 
51 2 111 125 219 318   3.1 3.4 3.9 4.6   
52 1 32 43       1.8 2.7       
53 2 23 27 35     3.5 3.5 4.2     
54 1 109 96 124     2.7 3.1 3.5     
55 1 79 164 135 81   1.5 1.8 1.8 2.0   
56 1 77 96 128 122   1.5 1.4 1.9 1.7   
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Patient 
TPN 
sample 1 
TPN sample 
2 
TPN sample  
3 
TPN sample 
4 
TPN sample 
5 
Glutamine 
sample 1 
Glutamine 
sample 2 
Glutamine 
sample 3 
Glutamine 
sample 4 
Glutamine 
sample 5 
1 0 1 1 1 1 0 0 0 0 0 
2 0 1 1   0 0 1 1   0 
3 0 1 0     0 1 0     
4 0 1 1 1 1 0 0 0 0 1 
5 0 1 0 0 0 0 1 0 0 0 
6 0 1 1 1   0 1 1 1   
7   1 1 1     0 0 0   
8 0 1 1 1 0 0 1 1 1 0 
9 0 1 1 1 1 0 1 0 0 0 
10 0 1 1     0 1 1     
11 0 1 1     0 1 1     
12 0 1 1 0 0 0 1 1 0 0 
13 0 1 1 1 0 0 0 0 0 0 
14 0 1 1 1 1 0 1 1 1 1 
15 0 1 1 1   0 1 1 1   
16 0 1 1   0 0 1 1   0 
17 0 1 1 1 1 0 1 1 1 1 
18 0 1       0 1       
19 0 1 1 0 0 0 1 1 0 0 
20 0 1 0 0   0 1 0 0   
21 0 1 1 0   0 1 1 0   
22 0 1       0 1       
23 0 1 1 1 1 0 1 1 1 1 
24 0 1 1 1 0 0 0 0 0 0 
25 0 1 1 0 0 0 1 1 0 0 
26 0 1 1 1 1 0 0 1 1 1 
27 0 1 1 1   0 0 0 0   
28 0 1 1 0   0 1 1 0   
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Patient 
TPN 
sample 1 
TPN sample 
2 
TPN sample  
3 
TPN sample 
4 
TPN sample 
5 
Glutamine 
sample 1 
Glutamine 
sample 2 
Glutamine 
sample 3 
Glutamine 
sample 4 
Glutamine 
sample 5 
29 0 1 1     0 1 1     
30   1 1 0 0   0 0 0 0 
31                     
32 0 1 1 0   0 0 1 0   
33   1 1       1 1     
34   1 1 1     0 0 0   
35 0 1 0 0 0 0 0 0 0 0 
36 0 1 1     0 1 1     
37           
38 0 1 1 1 1 0 0 0 0 1 
39 0 1 0 0 0 0 1 0 0 0 
40 0 1 1 1 0 0 1 1 1 0 
41 0 1 1     0 0 0     
42 0 1 1 1   0 0 0 0   
43 0 1 1 1   0 1 1 1   
44 0 1 1 1 1 0 1 1 1 1 
45 0 1 1 0 0 0 1 1 0 0 
46 0 1 1     0 0 0     
47 0 1 0 0 0 0 1 0 0 0 
48 0 1 1 1 1 0 1 1 1 1 
49 0 1 1 0   0 1 1     
50 0 1 1 1 0 0 0 0 1 0 
51 0 1 1 1   0 1 0 1   
52 0 1       0 1       
53 0 1 1     0 0 0     
54 0 1 0     0 0 0     
55 0 1 1 1   0 0 0 1   
56 0 1 1 1   0 0 0 0   
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Patient 
Glucose 
(mmol/L) 
sample 1 
Glucose 
(mmol/L) 
sample 2 
Glucose 
(mmol/L) 
sample 3 
Glucose 
(mmol/L) 
sample 4 
Glucose 
(mmol/L) 
sample 5 
Glucose 
Group 
sample 1 
Glucose 
Group 
sample 2 
Glucose 
Group 
sample 3 
Glucose 
Group 
sample 4 
Glucose 
Group 
sample 5 
1   4,6 5,5 6,6     1 1 1   
2 5,1 7,1       1 2       
3 5,7 6,8       1 1       
4 4,6 9,7 6,2 8,6 10 1 2 1 2 2 
5 7,6 10,9 4,9     2 3 1     
6 7,9 7,3 8,4     2 2 2     
7   6,9         1       
8   5,9 6,4       1 1     
9 6,8 8,7     10 1 2     2 
10 6,2         1         
11   5,6         1       
12 4,2 5,8 5,7 7,5 7,9 1 1 1 2 2 
13 5,5 6,8 10,2 6,3 6,2 1 1 3 1 1 
14 9,3 7,3 6,9 7,7   2 2 1 2   
15 6,6 5,2       1 1       
16   6,3 7       1 1     
17         6,4         1 
18 8,5 5,5       2 1       
19 7,7 6,5 7,4     2 1 2     
20 4,2         1         
21 6,4 6 5,1 6,4   1 1 1 1   
22 7,3 6,5       2 1       
23 4,9 5,8 6,5 7,9   1 1 1 2   
24 4,4 7,3 6,7     1 2 1     
25 5,4 7,3 7     1 2 1     
26 4,6 4,2 6,9 6,8 5,7 1 1 1 1 1 
27     5,7 5,7       1 1   
28 4,9 8       1 2       
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Patient 
Glucose 
(mmol/L) 
sample 1 
Glucose 
(mmol/L) 
sample 2 
Glucose 
(mmol/L) 
sample 3 
Glucose 
(mmol/L) 
sample 4 
Glucose 
(mmol/L) 
sample 5 
Glucose 
Group 
sample 1 
Glucose 
Group 
sample 2 
Glucose 
Group 
sample 3 
Glucose 
Group 
sample 4 
Glucose 
Group 
sample 5 
29 6,6 7 12,4     1 1 3     
30     5,7         1     
31                     
32 6,4 6,3       1 1       
33   6,1         1       
34   6,5 5,9       1 1     
35 6,5 8 5,5 5,2 5,5 1 2 1 1 1 
36 5,5 6,6 6,1     1 1 1     
37                     
38 6,7 7,3 5,6 9,6   1 2 1 2   
39 7 8,6 8,5 8,6   1 2 2 2   
40 6,3 9,4 4,2 7,8 8,1 1 2 1 2 2 
41 4,4   5,6     1   1     
42 5,5   6,7     1   1     
43 4,5 8 5,2 5,5   1 2 1 1   
44 6,9 8,6   8   1 2   2   
45   6,7 4,5       1 1     
46   6,7 5,3       1 1     
47 5,1 6,4 8,3 7,4 9,8 1 1 2 2 2 
48 7,6 7,7 6,2   7,1 2 2 1   2 
49 5,7 7,1       1 2       
50     7,9         2     
51   6,7 5,7       1 1     
52 5,8 7,6       1 2       
53     6,9         1     
54 5,6 6,2 6,9     1 1 1     
55 4,1 9,1 6,2 5,8   1 2 1 1   
56 5,8 5,6 7,5 5,9   1 1 2 1   
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Table 4.8: Comparison of Covariance Structures in IGF-1 for "full" model 
(ITU_Ward TPN Glutamine Glucose_Group CRP Day_Group). 
 
Covariance Structure of IGF-1 
AIC 
(smaller 
is better) 
Number of 
Parameters 
Compound Symmetry 1379.4 2 
Heterogeneous Compound Symmetry 1353.0 6 
First-Order Autoregressive 1365.9 2 
First-Order Autoregressive with random patient 1366.9 3 
Heterogeneous First-Order Autoregressive 1352.6 6 
Spatial Power (Day) 1363.7 2 
Spatial Power (Day) with random patient 1364.5 3 
 
Table 4.9: Comparison of Covariance Structures in FT3 for "full" model (ITU_Ward 
TPN Glutamine Glucose_Group CRP Day_Group). 
Covariance Structure of FT3 
AIC 
(smaller is 
better) 
Number of 
Parameters 
Compound Symmetry 337.2 2 
Heterogeneous Compound Symmetry 342.0 6 
First-Order Autoregressive 336.2 2 
First-Order Autoregressive with random patient 334.9 3 
Heterogeneous First-Order Autoregressive 342.6 6 
Spatial Power (Day) 345.7 2 
Spatial Power (Day) with random patient 338.9 3 
 
 
Table 4.10: Mixed model 1: p value of variables ICU_Ward, TPN, Glutamine, 
Glucose_Group, CRP and Day_Group for the final outcome measure IGF-1. 
 
Effect on IGF-1 
Num 
DF 
Den 
DF F Value Pr > F 
ICU_Ward 1 61.7 5.60 0.0211 
TPN 1 60.1 0.20 0.6543 
Glutamine 1 71.6 2.59 0.1121 
Glucose_Group 2 69.1 0.54 0.5871 
CRP 1 91 0.53 0.4683 
Day_Group 4 35.1 4.65 0.0041 
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Table 4.11: Mixed model 1: p value of variables ICU_Ward, TPN, Glutamine, 
Glucose_Group, CRP and Day_Group for the final outcome measure FT3. 
 
Effect on FT3 
Num 
DF 
Den 
DF F Value Pr > F 
ICU_Ward 1 64.7 2.96 0.0901 
TPN 1 93.5 0.12 0.7304 
Glutamine 1 114 0.25 0.6180 
Glucose_Group 2 81.5 0.30 0.7452 
CRP 1 99.8 0.02 0.8782 
Day_Group 4 82.8 9.88 <.0001 
 
Table 4.12: effect estimates on IGF-1 in relation to the reference category (estimate 
zero). 
Effect on IGF-1 
ICU_War
d TPN Glutamine Glucose_Group Day_Group Estimate 
Standard 
Error DF t Value Pr > |t| 
Intercept _ _ _ _ _ 122.44 29.2991 33.6 4.18 0.0002 
ICU_Ward ICU _ _ _ _ 25.2011 10.6458 61.7 2.37 0.0211 
ICU_Ward Ward _ _ _ _ 0 . . . . 
TPN _ No _ _ _ -6.9403 15.4222 60.1 -0.45 0.6543 
TPN _ Yes _ _ _ 0 . . . . 
Glutamine _ _ No _ _ 13.2133 8.2133 71.6 1.61 0.1121 
Glutamine _ _ Yes _ _ 0 . . . . 
Glucose_Group _ _ _ <=7 _ -16.9850 19.5129 57.2 -0.87 0.3877 
Glucose_Group _ _ _ > 7 & <=10 _ -19.4598 19.6092 58.4 -0.99 0.3251 
Glucose_Group _ _ _ >10 _ 0 . . . . 
CRP _ _ _ _ _ 0.02158 0.02963 91 0.73 0.4683 
Day_Group _ _ _ _ 1st sample -69.0190 25.0127 18.2 -2.76 0.0128 
Day_Group _ _ _ _ 2nd sample -50.4832 22.7070 14.8 -2.22 0.0422 
Day_Group _ _ _ _ 3rd sample -33.7037 21.9864 14 -1.53 0.1476 
Day_Group _ _ _ _ 4th sample -14.5530 20.6045 13.6 -0.71 0.4919 
Day_Group _ _ _ _ 5th sample 0 . . . . 
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Table 4.13: effect estimates on FT3 in relation to the reference category (estimate 
zero. 
Effect onFT3 
ICU_War
d TPN Glutamine Glucose_Group Day_Group Estimate 
Standard 
Error DF t Value Pr > |t| 
Intercept _ _ _ _ _ 4.2654 0.5105 106 8.36 <.0001 
ICU_Ward ICU _ _ _ _ -0.4394 0.2554 64.7 -1.72 0.0901 
ICU_Ward Ward _ _ _ _ 0 . . . . 
TPN _ No _ _ _ -0.09571 0.2770 93.5 -0.35 0.7304 
TPN _ Yes _ _ _ 0 . . . . 
Glutamine _ _ No _ _ 0.08834 0.1767 114 0.50 0.6180 
Glutamine _ _ Yes _ _ 0 . . . . 
Glucose_Group _ _ _ <=7 _ 0.1936 0.4359 77.4 0.44 0.6581 
Glucose_Group _ _ _ > 7 & <=10 _ 0.1096 0.4420 76.4 0.25 0.8049 
Glucose_Group _ _ _ >10 _ 0 . . . . 
CRP _ _ _ _ _ -0.00010 0.000654 99.8 -0.15 0.8782 
Day_Group _ _ _ _ 1st sample -1.4571 0.3214 68.7 -4.53 <.0001 
Day_Group _ _ _ _ 2nd sample -1.3088 0.2718 75.1 -4.82 <.0001 
Day_Group _ _ _ _ 3rd sample -0.8164 0.2634 85.5 -3.10 0.0026 
Day_Group _ _ _ _ 4th sample -0.5827 0.2487 94.2 -2.34 0.0213 
Day_Group _ _ _ _ 5th sample 0 . . . . 
 
 
 
Table 4.14: Final Mixed Model on IGF-1. Estimates of Fixed Effects. 
 
Effect on 
IGF-1 
ICU_War
d Day_Group Estimate 
Standard 
Error DF t Value Pr > |t| 
Intercept _ _ 107.73 20.1997 16.7 5.33 <.0001 
ICU_Ward ICU _ 27.0453 9.2844 51 2.91 0.0053 
ICU_Ward Ward _ 0 . . . . 
Day_Group _ 1st Visit -61.2200 19.7675 15.5 -3.10 0.0071 
Day_Group _ 2nd Visit -45.9183 19.5548 15.3 -2.35 0.0327 
Day_Group _ 3rd Visit -27.3372 19.2290 15.4 -1.42 0.1751 
Day_Group _ 4th Visit -12.3975 17.9688 15.1 -0.69 0.5007 
Day_Group _ 5th Visit 0 . . . . 
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Table 4.15: Final Mixed Model on FT3. Estimates of Fixed Effects. 
 
Effect on 
FT3 ITU_Ward Day_Group Estimate 
Standard 
Error DF t Value Pr > |t| 
Intercept _ _ 4.4116 0.2570 116 17.17 <.0001 
ITU_Ward ICU _ -0.4664 0.2269 54.5 -2.06 0.0446 
ITU_Ward Ward _ 0 . . . . 
Day_Group _ 1st Visit -1.4350 0.2244 63.7 -6.39 <.0001 
Day_Group _ 2nd Visit -1.2708 0.2222 69.5 -5.72 <.0001 
Day_Group _ 3rd Visit -0.8271 0.2232 83 -3.71 0.0004 
Day_Group _ 4th Visit -0.5549 0.2217 103 -2.50 0.0139 
Day_Group _ 5th Visit 0 . . . . 
 
 
 
Table 4.16: Absolute IGF-1 mean values and standard errors in patients 1 to 56. 
 
 
Effect ICU_Ward Day_Group 
IGF-1 Mean 
value estimate 
(ug/L) 
Standard error 
ICU_Ward ICU _ 105,4 7,76 
ICU_Ward Ward _ 78,4 8,4 
Day_Group _ Sample 1 60 4,86 
Day_Group _ Sample 2 75,3 5,28 
Day_Group _ Sample 3 93,9 6,82 
Day_Group _ Sample 4 108,9 10,33 
Day_Group _ Sample 5 121,3 19,59 
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Table 4.17: Absolute FT3 mean values and standard errors in patients 1 to 56. 
 
 
Effect ICU_Ward Day_Group 
FT3 Mean value 
estimate 
(pmol/L) 
Standard error 
ICU_Ward ICU _ 3,13 0,16 
ICU_Ward Ward _ 3,59 0,17 
Day_Group _ Sample 1 2,74 0,14 
Day_Group _ Sample 2 2,91 0,13 
Day_Group _ Sample 3 3,35 0,14 
Day_Group _ Sample 4 3,62 0,17 
Day_Group _ Sample 5 4,18 0,23 
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